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Enalaprilat N-{N-[(S)-l-carboxy-3-phenylpropyl]-L- 
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An orally-active inhibitor of angiotensin 
converting-enzyme.
G-protein guanine nucleotide-binding protein 
Gs stimulatory G-protein
G^ inhibitory G-protein
GQ 'other* G-protein.
_ . &H.77 D-His-Pro-Phe-His-Leu-Leu-Val-Tyr
H . 77 is an analogue of the His—Tyr13
octapeptide sequence of equine
angiotensinogen in which the N-terminal
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IBMX
i.v.
JG
NPY
PAGE
PDGF
SBTI
SV40
TEMED
Tween
histidine residue has been replaced with D- 
histidine and the cleavage site has been 
modified by the introduction of a reduced 
peptide bond (R: -CH2-NH-) in place of the
peptide bond normally cleaved by renin.
3-i sobuty1-1-methy1xanthine 
intravenous 
juxtaglomerular 
neuropeptide Y
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platelet-derived growth factor 
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simian virus 40
N, N, N *, N '-tetramethylethylenediamine 
20 polyoxyethylenesorbitan monolaurate
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SUMMARY
A novel in vitro model system has been used to study 
the control of renin release. Human cultured
nephroblastoma cells, which secrete active renin and 
prorenin at high levels, were used to investigate the 
intracellular messengers that are involved in the renin 
secretory response to hormones (e.g. Aj j, ANP) and drugs 
(e.g. isoprenaline, Enalaprilat).
1. The present study showed that treatment with 
isoprenaline, dbcAMP or forskolin stimulated active renin 
release at 5h.
2. Long-term (up to 12 days) treatment with isoprenaline, 
dbcAMP or forskolin caused stimulation of renin release and 
nephroblastoma cell growth.
Isoprenaline and dbcAMP did not increase the amount of 
renin secreted per cell. The apparent increase in renin 
secretion was due to an increase in the number of renin- 
secreting cells.
By contrast, forskolin increased renin secretion per
cell.
3. Propanolol blocked the action of isoprenaline on renin 
secretion and cell growth.
4. ANP inhibited basal renin release and this was blocked 
by pertussis toxin.
5. ANP reduced ^-agonist-stimulated renin release.
6. ANP reduced isoprenaline- and dbcAMP-stimulated cell 
growth.
22
7. Isoprenaline and forskolin stimulated intracellular 
[cAMP]. Isoprenaline caused an immediate response (within 
1 min) which peaked early (at 5 mins) and was followed in 
time (at lh) by an increase in renin release.
Forskolin caused a sustained response which was 
paralleled (in time) by an increase in renin release.
8. ANP caused a significant stimulation of cGMP release 
from the cells, which paralleled the inhibition of basal 
active renin release.
9. ANP reduced the isoprenaline-stimulated increase in 
intracellular [cAMP] and renin release.
10. ANP reduced forskolin-stimulated renin release but 
potentiated the forskolin-induced rise in [cAMP]j.
11. The ANP-induced rise in cGMP release was reduced by 
isoprenaline and forskolin, but forskolin was less 
effective than isoprenaline.
12. Ajj reduced basal renin release at 5h.
13. Long-term treatment with Aj j inhibited both active and 
total renin release. Long-term treatment with AII had no 
effect on cell growth.
14. Ajj concentrations were high in the medium to which no 
A n  hac* been added. These could be reduced by Enalaprilat 
with a concomitant stimulation of renin release, indicating 
A n  fee<ikack inhibition on the cells.
15. Long-term treatment of the cells with Enalaprilat 
caused stimulation of active renin but not prorenin 
release. Long-term treatment with Enalaprilat had no
23
effect on cell growth.
16. The presence of Gs and G^2 was detected in membrane 
preparations from cultured nephroblastoma cells, using 
SDS/PAGE and immunoblotting.
17. Immunocytochemistry, electron microscopy and karyotype 
analysis showed that the cells exhibited mesenchymal 
differentiation, had an ultrastructure indicative of some 
smooth muscle" differentiation and had a 46XX karyotype.
In conclusion, results from the present study show 
that the nephroblastoma cell model system has proved to be 
a valuable model in vitro for investigating second 
messenger involvement in the control of human renin 
release.
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CHAPTER 1
INTRODUCTION
1.1 The aspartvl proteinase, renin
Renin (E.C.3.4.23.15.) is a highly specific aspartyl 
proteinase. It is the first and rate-limiting enzyme of 
the renin-angiotensin system, catalysing the formation of 
angiotensin I (Aj) from renin substrate, angiotensinogen 
(Figure 1.1). Subsequently Aj is cleaved by converting- 
enzyme to form angiotensin II (Aj j), which is involved in 
fluid and electrolyte balance and in the control of blood 
pressure.
Renin is an enzyme which, together with such enzymes 
as pepsin and cathepsin D, is considered an aspartyl 
proteinase because of the presence of two aspartic acid 
residues at the active site which are involved in 
catalysis. The presence of two catalytically active 
aspartic /3-carboxyl groups in the active sites of aspartic 
proteinases was deduced from pH dependence and alkylation 
experiments (Fruton, 1976). The proposed general acid- 
general base catalytic mechanism for action of aspartic 
proteinases in converting substrate to products is depicted 
in Figure 1.2.
In this mechanism, direct addition of water leads to 
the formation of a tetrahedral intermediate (Rich et al., 
1982) before the peptide bond is broken in the catalytic 
reaction.
The two aspartyl groups in the enzyme which provide
25
Figure 1•1:
Ang iotens inogen
Renin* is the rate-determining step of the 
renin-angiotensin system.
Renin mRNA
Prorenin
i .
Renin* Convertmg-
Enzyme
y \  Angiotensin I n/ n. Angiotensin II 
^  (Aj) 7  (An)
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IGeneral acid - 
General base
—  Asp
OH R 
—  NH
OH
HO —  C —  Asp
I
0 R 2
’NH\ / \ 0H +  H2N
R1
O
Figure 1.2: Schematic representation of proposed catalytic 
mechanism for action of aspartic acid 
proteinases in converting substrate to 
products. (Source: Rich, 1985).
Direct addition of water leads to formation of 
a tetrahedral intermediate* (Rich et a_l. ,
1982) .
essential carboxyl groups for the cleavage reaction are a 
highly conserved feature of the active site of the enzyme, 
which resembles that of other acid proteinases, in 
particular that of pepsin.
The human renin gene has been sequenced (Imai et al., 
1983? Hardman et al., 1984? Hobart et al., 1984) and the
structure of the human renin and human pepsinogen genes are 
remarkably similar (Sogawa et al., 1983). Both genes are 
composed of 10 exons (coding sequences) and 9 introns 
(Hardman et al., 1984). The size of the corresponding
exons and the location of introns in the expressed gene 
sequence for renin and pepsinogen are nearly congruent. 
For example there is 66% homology between the amino acid 
sequences of exon 3, which includes the first catalytic 
aspartyl residues for both human renin and human 
pepsinogen.
The mouse submaxillary gland renin gene was sequenced 
by Panthier et al. in 1982, and the mature, human renin 
peptide is 68% homologous in amino-acid sequence to the 
mouse enzyme. The two coding nucleotide sequences are 77% 
homologous (Hobart et al., 1984).
The similarities in the structure of the human renin 
and human pepsinogen genes support the view that the 
mammalian aspartyl proteinase family of enzymes (which 
includes chymosin and cathepsin D) share a common protein 
structure which is essential for activity (Blundell et al.,
1983). This conserved structure is apparently built from 
peptide domains of similar size that are encoded from
28
individual exons. Therefore, aspartyl proteinases exhibit 
conserved homology in their primary, secondary and tertiary 
structures.
Recently, it has been reported by Lapatto et al. 
(1989) that the structure of the human immunodeficiency 
virus-1 (HIV-1) proteinase corresponds closely in certain 
areas of its primary, much of its secondary and most of its 
tertiary structure to the established structure of the 
aspartyl proteinases.
The substrate specificity of the aspartyl proteinases 
differs widely. For example, pepsin splits its substrate 
at all the internal aromatic residues. Renin, however, is 
unique in having a very high degree of specificity and 
shows no general proteolytic activity. Indeed, renin 
cleaves at only one site in a single peptide substrate, 
angiotensinogen and, unlike other aspartyl proteinases, 
primate renin is species-specific (Braun-Menendez et al.. 
1946).
Comparative amino terminal sequences for 
angiotensinogen from a number of species are listed in 
Table 1.1. The minimum peptide sequence required for the 
substrate to be active comprises an octapeptide (Skeggs et 
al., 1968a). Renin specifically cleaves the peptide bond
between the amino acid residues at positions 10 and 11. In 
the horse, dog and rat, this is a leucyl-leucine bond. In 
the human, it is a leucyl-valine scissile bond. This 
reflects the species-specificity of the renin-substrate
29
Table 1.1
Comparison of the N-terminal sequences of human, equine, 
canine and rat angiotensinogens.
Renin cleavage 
site
1 2 3 4 5 6 7 8 9 V  10 11 12 13 14
Humana asp arg val tyr ile his pro phe his leu val ile his asn
Equineb asp arg val tyr ile his pro phe his leu leu val tyr ser
Caninea asp arg val tyr ile his pro phe his leu leu val tyr ser
Rata asp arg val tyr ile his pro phe his leu leu tyr tyr ser
Key: a. Data from Burton and Quinn, 1988. 
b. Data from Skeggs et al., 1968b.
30
reaction.
Renin differs from other aspartyl proteinases, such as 
pepsin, penicillinopepsin and chymosin (Tang, 1973) in that 
its activity is not optimal at acid pH. The purified 
animal renins have a broad pH optimum in the range pH 5.5 
to pH 7.0 when tested with homologous renin substrates 
(Inagami et al., 1977). Human kidney renin has a narrower 
pH optimum when acting on human substrate, at pH 6.0 
(Yokosawa et al., 1980).
1.2 Renin biosynthesis
Human renin is synthesized and stored mainly in the 
juxtaglomerular (JG) cells of the afferent glomerular 
arteriole of the kidney (Lacasse et al., 1985). Like other 
proteinases, renin is synthesized as a preproenzyme. 
Processing of renin involves sequential proteolytic 
cleavages of the preproform to the active, mature form 
(Figure 1.3a). Preprorenin is rapidly transferred to the 
rough endoplasmic reticulum and hydrolysed, probably by a 
signal peptidase, to produce prorenin. Prorenin is 
processed at paired basic amino acids in its amino-terminal 
region and the resultant active, mature renin is stored in
r
granules until its release is stimulated (Figure 1.3b) 
(Pratt et al., 1983; Hirose et al., 1985). However, the
nature of the intracellular sorting signal, the location of 
renin precursor processing and the enzyme(s) responsible 
are currently unknown.
Both prorenin and active renin are released by the 
kidney into the circulation. Recently, the presence of
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Figure 1.3a: Schematic representation of the possible 
maturation process of human kidney renin.
LysArg Leu 
65 66 67
Met Arg
406
LysArg Leu Arg
40621
Pro Renin
Pre Pro Renin
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67____________________ 406
Renin
71* 141*
Asn Asn
Adapted from: Imai et a^. , 1983.
(a) Proposed sites of processing of leader sequence and 
prosequence are indicated by single and double 
arrowheads, respectively, as predicted by comparison 
with the mouse renin precursor (Panthier et al., 1982) 
and human prepepsinogen (Sogawa et a_l. , 1983).
Potential N-glycosylation sites are denoted by 
asterisks. The mature protein is composed of 340 amino 
acid residues.
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Figura 1.3.b. Intracellular pathway(3 ) of renin 
synthesis and release.
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(b) Proposed intracellular localization of the various 
forms of renin during biosynthesis and secretion.
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more than one pathway of renin secretion has been suggested 
by several groups of investigators (Fray, 1978? Katz and 
Malvin, 1982? Pratt et al., 1983). In one pathway (Figure 
1.3b), active renin is stored in granules before release, 
while in another pathway, newly synthesized prorenin is 
secreted directly.
Although renin is generally considered to be a renal 
enzyme, it has been found in a number of other tissues such 
as uterus and placenta (Symonds et al., 1968); blood
vessel walls (Re et al., 1982) and brain (Inagami et al., 
1982) particularly the anterior pituitary (Saint Andre, 
1986) (for review, see Deboben et al., 1983). Recently,
considerable attention has been given to extrarenal sites 
of renin expression, and there is evidence for renin 
synthesis in many organs, including the adrenal gland, 
testis, ovary and brain (Hirose et al., 1980? Naruse et
al., 1984? Kim et al., 1987).
Although the significance of such expression is not 
yet understood, recent studies suggest that local synthesis 
of Ajj promotes angiogenesis (Fernandez et al., 1985) and 
may be important for ovulation (Pellicer et al., 1988).
This suggests that the renin-angiotensin system has 
physiological functions in addition to its classic role in 
the maintenance of blood pressure.
1.3 The renin-angiotensin system
Renin is secreted by the kidney into the bloodstream, 
where it cleaves the a2-globulin, angiotensinogen, to 
produce the inactive decapeptide, angiotensin I (Aj)
34
(Figure 1.4). Subsequently, the C-terminal dipeptide of Aj 
is cleaved by angiotensin converting-enzyme to produce the 
potent vasoactive octapeptide angiotensin II (Aj j). Ajj 
has a very short half-life (approx. 20s.) in the blood 
(Ferreira and Vane, 1967) and the concentration of 
circulating renin is the major, rate-limiting step in the 
production of Ajj in vivo. Ajj is a potent vasoconstrictor 
and has other actions (Figure 1.4) such as stimulation of 
aldosterone secretion from the adrenal cortex and 
stimulation of smooth muscle cell growth (Lyall et al., 
1988a) . Therefore, Ajj is important in cardiovascular 
homeostasis (Brown et al., 1983).
Up to 90% of human plasma renin exists in an inactive 
form, which is believed to be the biosynthetic precursor of 
the active enzyme (Leckie et al., 1977; Sealey et al.,
1980? Hsueh, 1984). Conversion of prorenin to active renin 
probably does not occur in the plasma. However, this 
inactive renin may be used for local production of active 
renin by specific tissues. (Section 1.2).
Prorenin, the inactive precursor of active renin can 
be found in the circulation under certain circumstances 
when the kidneys are absent (Sealey et al. , 1977).
However, the kidney is the only organ where secretion of 
active renin has been conclusively demonstrated (Deboben et 
al., 1983? Pandey et al., 1985? Ohashi et al., 1985).
Plasma renin levels which are markedly elevated or 
suppressed in comparison with the normal range are often
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indicative of certain disease states. For example, renal 
hypertension is often associated with increased levels of 
plasma active renin (Millar et a l ., 1978), whereas
nephroblastoma patients have elevated levels of circulating 
prorenin (Carachi et al., 1987a).
1.4 Physiological control of renin release
Renin secretion is under tight control physiologically 
and it is generally recognized that three groups of 
mechanisms are involved in the control of renin release: 1) 
two intrarenal receptors? the renal vascular receptor and 
the macula densa 2) the renal sympathetic nerves and an 
adrenergic receptor and 3) several humoral agents including 
circulating catecholamines, sodium (Na+) and potassium 
(K+) ions, Ajj, anti-diuretic hormone (ADH) and atrial 
natriuretic peptide (ANP). The interrelationships of the 
vascular receptor, the macula densa, the JG cells, the 
afferent and efferent arterioles and the renal sympathetic 
nerves are depicted diagrammatically in Figure 1.5.
The three main groups of control mechanisms were 
identified through the use of animal models, such as 
conscious dogs (Goldblatt et al.., 1934); perfused dog
kidneys? sodium depleted dogs with a denervated kidney? 
isolated rat kidneys? mouse kidney experiments and also 
studies involving human patients, including tilting in man 
(Hollenberg et al.. , 1969). The various physiological
mechanisms involved in renin release have been reviewed 
thoroughly by Davis and Freeman (197 6) and also more 
recently, by Keeton and Campbell (1981).
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Figure 1.5: Diagram of renal juxtaglomerular apparatus,
which includes the JG cells and macula densa in their close 
physical relationship. Dark granules in JG cells are 
renin-containing granules. Renal vascular receptor 
includes JG cells and adjacent renal afferent arteriole. 
Renal nerves are shown ending in both JG cells and smooth 
muscle cells of renal afferent arteriole. (From, Davis 
(1971)).
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Comparatively little work has been done on the 
intracellular control of renin release i.e. from the 
receptor to the effector. Indeed, the sequence of 
intracellular events within the JG cell, leading to the 
release of renin, in response to extrinsic stimuli, remains 
poorly defined. Extrinsic stimuli, such as /9-adrenergic 
agonists, Ajj or ANP are thought to affect the activity of 
the renin-secreting cell by altering its intracellular 
concentrations of certain second messengers.
1.5 Second messengers involved in the control of renin
release
The main second messengers reported to be involved in 
the control of renin release are?
1)Adenosine 3 *,5'-cyclic monophosphate (cAMP).
2) Calcium and 3)Guanosine 3f,5'-cyclic monophosphate (cGMP).
1.5.1. cAMP;
cAMP is a stimulatory second messenger in many 
secretory cells (Rubin, 1982) and is almost certainly, a 
stimulatory second messenger in renin secretion (Peart et 
al., 1975? Hofbauer et al., 1978? Churchill and Churchill, 
1982a). This is because, renin secretion is stimulated by 
many substances that are known to activate adenylate 
cyclase (p-adrenergic agonists (Pinet et & 1 ., 1987)? A2 
adenosine receptor agonists? dopamine? glucagon and 
forskolin (Seamon and Daly, 1981)) and inhibited by other 
substances known to inhibit adenylate cyclase (a-adrenergic
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agonists and A^  ^ adenosine receptor agonists) . Moreover, 
renin secretion is stimulated by exogenous cAMP (Michelakis 
et al. . 1971) and/or dibutyrylcAMP (dbcAMP) and by
phosphodiesterase inhibitors (Peart et al., 1975).
0-Adrenergic agonists stimulate adenylate cyclase 
(E.C.4.6.1.1.). The adenylate cyclase enzyme system is 
composed of at least 3 distinct protein components: a
hormone receptor; a guanine nucleotide-binding protein (G- 
protein) which mediates hormonal activation and a catalytic 
subunit which converts the substrate ATP to cAMP (Rodbell, 
1980). Adenylate cyclase can be regulated in both positive 
and negative fashion by hormones and neurotransmitters. In 
each case, receptor control of cAMP production is mediated 
via a G-protein, Gs for the stimulation of adenylate 
cyclase activity resulting in an increase in intracellular 
cAMP levels and G^ for inhibition of enzyme activity, which 
is associated with reduced signal transduction by adenylate 
cyclase (Gilman, 1987? Spiegel, 1987).
1.5.2. Calcium:
Calcium is a stimulatory second messenger in most 
secretory cells (Rubin, 1970). However, the available 
evidence indicates that calcium is an inhibitory second 
messenger in renin secretion (Peart et al., 1975? Fray,
1980? Churchill and Churchill, 1982a? Churchill, 1985). But 
renin is not unique in being a secretory protein triggered 
by a lowering of cytosolic calcium. Notable other examples 
are parathyroid-hormone (Wallace and Scarpa, 1982; Habener 
et al., 1984)? glucagon (Leclercg-Meyer and Malaisse, 1983)
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and human placental lactogen (Handwerger et al., 1981).
Since JG cells are thought to be derived from smooth 
muscle cells (Barajas, 1979), a logical conclusion was that 
smooth muscle contraction and renin inhibition induced by 
An, dePend on the concentration of intracellular calcium 
([Ca2+]±).
In normal conditions, JG cells are estimated, to contain
(Park et al., 1986) 
approximately O.ljxM free Ca2+ in the cytoplasmic space.A JG
cells in vivo, are bathed by extracellular fluid which
usually contains between 1 and 3mM Ca2+ (Figure 1.6a). JG
cell membranes are also electrically polarized (Fishman,
1976? Buhrle et al., 1985) with the intracellular fluid
being approximately 70mV negative, with respect to the
extracellular fluid (Figure 1.6a).
Consequently, there is a large electrochemical 
gradient which favours the influx of Ca2+ i.e. the 
electrical potential and the 1,000 to 10,000-fold 
difference in concentration (Figure 1.6a). In order to 
maintain this high concentration gradient for Ca2+, the 
cells utilize at least 3 mechanisms: (1) a low basal
permeability of the plasma membrane for Ca2+, to prevent 
excessive influx? (2) a highly efficient Ca2+ efflux 
mechanism(s), to extrude residual Ca2+ and (3) 
intracellular systems to sequester excess Ca2+ (e.g. 
mitochondrial uptake, uptake into calciosomes (Burgoyne, 
1989).
Inhibitory first messengers could increase JG cell 
[Ca2+]^ in several ways? decreased Ca2+ efflux across the
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Figure 1.6.a: Hypothetical JG cell. Large electrochemical 
gradient favouring Ca2 + influx suggests that efflux 
pathways must exist even though intracellular Ca2+ can be 
buffered by mitochondrial uptake, by sequestration in 
endoplasmic reticulum and by Ca2+-binding molecules such as 
proteins and nucleotides (from Churchill, 1985).
Vottage-sensrtiv* channel
Receptor-operated channel
Figure 1.6.b: Hypothetical JG cell membrane with voltage- 
sensitive and proposed receptor-operated channels . Voltage 
sensitive channels for K+, Na+ and „Ca2+ have been described 
in many cells. "Receptor-operated channels are activated 
when an agonist occupies its receptor on the cell membrane. 
Angiotensin, vasopressin and adenosine probably activate JG 
cell “receptor-operated" channels (from Churchill, 1985) .
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membrane; increased Ca2+ influx, and/or mobilization of 
Ca2+ from intracellular sites of sequestration/binding.
The hypothesis that JG cells have two main mechanisms 
for regulating/changing [Ca2+]^  has been widely reported in
the literature. The two mechanisms are; (1) voltage-
proposed
operated Ca* channels and (2 )A receptor-operated Ca^ 
channels (Figure 1.6b).
Some first messengers increase [Ca2+]^  by depolarizing 
the cell membrane e.g. membrane-depolarizing concentrations 
of extracellular K+ (Park and Malvin, 1978? Churchill and 
Churchill, 1982b) or calcium ionophores. However, the 
inhibitory effects are blocked by calcium channel 
antagonists, such as verapamil (Park et al., 1981), which 
suggests that Ca2+ influx mediated (at least partly) the
inhibitory effect of; depolarization, or Ca2+ ionophores.
have been, proposed, to  0 ,
Other first messengersAactivate "receptor-operated Caz
channels resulting in a Ca2+ influx and/or mobilization,
which seems to be independent of membrane potential (Figure
- —    activate
1.6b) .It has also been proposed that Ajj and vasopressin A
ptor-operated" Ca2+ channels.In addition, it has already been shown
that Ajj causes Ptdlns4,5P2/PtdIns4P hydrolysis in cultured
vascular smooth muscle cells with rapid formation of
Insl,4P2/Inslr4,5P3 and a diacylglycerol (DG) peak
(Griendling et al., 1986). Insl,4,5P3 has been shown to
induce calcium release from nonmitochondrial storage sites
(Berridge and Irvine, 1984) . Evidence is accumulating
which suggests that activation of protein kinase C by DG
and increased [Ca2+]^  is the next step in the sequence of
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events leading to alterations in the activity of some cells 
(Churchill and Churchill, 1984? Berridge, 1984).
Whether this is also true for Ajj inhibition of renin 
release from JG cells is, as yet, not firmly established.
Also, tumour-promoting phorbol esters, such as 12-0- 
tetradecanoyl phorbol 13-acetate (TPA) activate protein 
kinase C by substituting for DG and by increasing the 
affinity of protein kinase for ambient Ca2+ .^ TPA was found 
to inhibit renin secretion, in a concentration-dependent 
manner, in rat renal cortical slices (Churchill and 
Churchill, 1984).
Adenosine inhibits renin secretion in vivo (Spielman 
and Thompson, 1982) and adenosine analogues selective for 
activation of A^ adenosine receptors inhibit renin 
secretion in isolated, perfused rat kidneys (Murray and 
Churchill, 1984) and in rat renal cortical slices 
(Churchill and Churchill, 1985), probably by receptor- 
dependent hydrolysis of phosphoinositides, in an analogous 
fashion to that reported for Ajj and vasopressin.
1.5.3. cGMP:
There is evidence to indicate that renal renin 
secretion is inhibited by ANP (Garcia et al., 1985); a
natriuretic and diuretic peptide produced by the cardiac 
atria of several mammalian species, including man (De Bold 
et &1., 1981? Kangawa and Matsuo, 1984). In the kidney, 
ANP interacts with guanylate cyclase-linked receptors 
(Ohlstein and Berkowitz, 1985) resulting in increased cGMP
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concentration in glomeruli and distal tubules. Increased 
release of cGMP can alter Ca2+ fluxes (Cornwell and 
Lincoln, 1989) and cAMP levels in some cells (Ishikawa et 
al., 1985? Anand-Srivastava, 1985) and, therefore, cGMP is 
emerging as a second messenger of increasing importance in 
the control of renin release.
Kurtz et al. (1986) have reported that inhibition of 
renin release by ANP in cultured rat JG cells was 
paralleled by an increase in cellular cGMP levels. The 
mechanism of elevation of cGMP by ANP is due to activation 
of the particulate isoenzyme form of guanylate cyclase 
(Winquist et al., 1984? Tremblay et al., 1985? Murad, 1986) 
and stimulation of particulate guanylate cyclase by ANF has 
been demonstrated for a number of different tissues 
(Winquist et al., 1984? Hamet et al., 1984? Matsuoka et 
al., 1985).
There are increasing numbers of reports concerning ANP 
receptor subtypes in various tissues, and cDNAs encoding 
two separate receptor proteins have recently been cloned 
(Fuller et al., 1988? Chinkers et al., 1989). Maack et al. 
(1987) proposed the model of two types of human ANP (hANP) 
receptors and their functions. One is the *B* receptor 
which is coupled with the membrane form of guanylate 
cyclase (particulate) and is responsible for the biological 
activity of ANP.
Another is the *0* receptor which is not coupled with 
guanylate cyclase and is probably responsible for the 
clearance of ANP. Presumably a guanylate cyclase-linked
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receptor is involved in the ANP-induced suppression of 
renin release.
However, the effect of ANP on renin secretion is still 
controversial, as some authors (Burnett et al., 1984) have 
reported an inhibition of renin release in models such as 
the perfused dog kidney and others (Hackenthal £t al., 
1985) have reported a stimulation of renin secretion in the 
isolated, perfused rat kidney.
Also, pharmacological discrepancies of ANP action, 
such as those reported by Resink et al. (1988), raise the 
possibility that changes in cGMP are an associated 
phenomenon rather than a primary mechanism of ANP action.
Therefore, at present, details of the molecular 
mechanism by which ANP alters renin secretion are still 
unclear.
1.6. Ca2+—cAMP(-cGMP) interactions
Theoretically, if both Ca2+ and cAMP are second 
messengers, they could act independently or they might act 
sequentially in either of two ways: increased [cAMP]^ leads 
to decreased [Ca leads to increased renin secretion or 
alternatively: decreased [Ca2+]^  leads to increased [cAMP]^ 
leads to increased renin secretion. These theoretical 
possibilities are illustrated in Figure 1.7 and are 
supported by the observations that increased [Ca2+]^ can 
lead to decreased [cAMP]^ (by inhibiting adenylate cyclase 
and/or by stimulating phosphodiesterase(s)) and that 
increased [cAMP]^ can lead to decreased [Ca2+]^ by
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Figure 1.7: A schematic of possible interactions between 
Ca + and cAMP second messenger systems in renin secretion
Experimental observations indicate that Ca is inhibitory 
(top) and that cAMP is stimulatory (bottom). Increased 
cAMP^ could decrease Ca2 + ^ by stimulating Ca2 + efflux 
and/or sequestration (pathway 1). Increased Ca2+  ^ could 
decrease cAMP^ by inhibiting its synthesis (adenylate 
cyclase; pathway 2) and/or by stimulating its destruction 
(phosphodiesterase; pathway 3) (as could cGMP*) (from 
Churchill, 1985).
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stimulating Na+-K+-ATP1ase and Na+-Ca2+ exchange and/or by 
stimulating Ca2+-ATP*ase) (reviewed by Rasmussen and 
Barrett, 1984). Thus, if acting sequentially, either Ca2+ 
or cAMP could theoretically be the predominant, or the
final, second messenger.
Pinet et al. (1987) showed that Ajj did not alter
basal cAMP release, and was also unable to reduce
forskolin-stimulated cAMP release although Ajj did reduce
forsko Lif\r 5 t'tm uLcrt ecL
/\ prorenin secretion. These results support the hypothesis
that cAMP and Ca2+ act independently on prorenin secretion,
but that the inhibitory effect of the rise in [Ca2+]^
predominates over the stimulatory effect of the rise in
[cAMP]^
Pinet et al. (1987) also investigated the role of ANP 
on forskolin-stimulated prorenin secretion, in a dose- 
dependent manner, and no change was observed in the 
forskolin-stimulated cAMP release although ANP did reduce 
forskolin-stimulated prorenin secretion. However, other 
authors have reported that ANP inhibits the forskolin and 
ADH-induced rise in cAMP (Ishikawa et al.. , 1985).
Therefore, cGMP most probably has an interactive role with 
cAMP (Figure 1.7).
Neuropeptide Y (NPY), a 36 amino-acid first isolated 
from porcine brain (Tatemoto and Mutt, 1980), possesses 
direct vasoconstrictor properties that are not dependent on 
simultaneous adrenergic activation. NPY has been shown to 
be a potent inhibitor of cAMP accumulation in feline
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cerebral blood vessels (Fredholm et al., 1985) and also to 
inhibit cardiac adenylate cyclase through a pertussis 
toxin-sensitive G-protein (Kassis gt al., 1987). Whether
it has the same effects on human JG cells and whether its 
actions are dependent on Ca2+ is, as yet, not firmly 
established.
The results obtained from cell culture systems, to 
date, support the view that /3-agonists, AII and ANP affect 
renin secretion by a direct action on human and rat JG 
cells. However, the intracellular signals involved and 
their exact interactions are, as yet, not well defined.
1.7. Tn vitro model systems used to date
The intracellular control of renin release is not well 
established. This reflects the limitations of the 
preparations used to study renin release in vitro. A major 
obstacle in preparing an in vitro model system is the fact 
that JG cells represent only 0.03% of the total cell 
population of the renal cortex (Fray and Park, 1987).
Most studies of renin secretion have been performed in 
complex systems, such as whole animals? the isolated,
perfused kidney? kidney cortex slices and isolated
glomeruli with attached afferent arterioles (Hackenthal et 
al., 1983). These systems included potential influences of 
endothelial, mesangial and vascular smooth muscle cells 
that are located close to the JG cells and, in these
preparations, it is impossible to measure cellular
responses and intracellular events in renin-secreting 
cells.
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The most suitable in vitro model appears to be the 
culture of highly purified JG cells. However, establishing 
JG cell cultures has, in the past, proved difficult, mainly 
because of the scarcity of these cells in the kidney. 
Primary cultures of renin-secreting cells from the rat were 
recently reported by Kurtz £t al. (1984). Also, primary 
cultures of renin-secreting cells have been described in 
the human in two cases of JG cell tumours (Conn et al., 
1972; Galen et al., 1984). Galen et al. (1984), cultured 
renin-secreting tumour cells for longer than one month in 
both primary and secondary cultures. In this study, renin 
was synthesized as an inactive precursor that had all of 
the biochemical and immunological characteristics of pure 
standard renin.
The sole attempt to maintain a rat JG cell culture has 
been made by Rightsel et al. (1982) (Table 1.2) by 
subculturing and cloning dissociated cortical cells from 
neonatal rat kidney.
Pinet et al. (1985) obtained continuous JG cell lines 
producing renin which they maintained by transfection with 
three different SV40 mutants. These cell lines provided a 
source of renin-producing cells available for the study of 
human prorenin regulation in vitro. However, the rate of 
renin secretion was low and more than 95% of the renin 
secreted into the medium was in an inactive form.
Also, Pratt et al. (1988) have transfected the human 
renin gene into established, cultured mammalian cell lines.
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The resultant cell lines contain the human gene stably 
integrated into the host cell genome, providing a 
consistent cell line for studies of renin biosynthesis and 
secretion. These authors compared renin biosynthesis and 
secretion in 3 transfected cell lines: mouse fibroblast
(L929) , Chinese hamster ovary (CHO) and mouse pituitary 
tumour (AtT-20) cells, but they did not carry out extensive 
studies, designed to look at the control of active and 
inactive renin release.
For a summary of the main in vitro model systems of 
renin release used to date, see Table 1.2.
1.8. Human nephroblastoma cells as an in vitro model
In the present study, cultured human nephroblastoma 
cells have been used as a model in vitro, to study the 
control of renin release at the second messenger level.
Nephroblastoma, or Wilms* tumour, is a paediatric 
neoplasm, derived from pluripotent mesodermal cells which 
can differentiate into all known structures of the normal 
kidney (Lindop et al., 1984). It has previously been shown 
by Carachi et al_. (1987a) , that patients with 
nephroblastoma have high, circulating concentrations of 
prorenin.
Cells were derived from an excised tumour and a 
primary culture was established by standard methods 
(Carachi et al., 1987b). Inglis and Leckie (1990) have
shown that nephroblastoma cells in culture, secrete both 
active renin and the enzymatically inactive precursor; 
prorenin, at high levels.
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Table 1.2:
In vitro model systems of renin release used to date.
In vitro model.
Cultured rat JG cells, 
(primary cultures)
Human tumoral JG cells, 
(primary cultures, secreted 
mainly inactive renin)
SV40 transformed 
tumoral JG cells.
(permanent line)
Cultured mouse JG cells, 
(primary cultures)
Cultured human mesangial 
cells, (long-term culture)
Cultured human chorionic 
cells, (possible permanent 
line).
Mouse pituitary AtT-20 
cells transfected with 
human renin gene, 
(permanent)
Authors.
Rightsel et al., 1982 
Kurtz et al., 1986
Conn et al., 1972 
Galen et al., 1984
Pinet et al., 1985 
Pinet et al., 1987
Lacasse et al., 1987
Chansel et al., 1987
Pinet et al., 1988
Fritz et al., 1987 
Pratt et al., 1988 
Nakayama et al., 1989
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Renin from the cultured cells was found to be 
identical to pure human renin from normal kidney in its 
binding to renin antibodies and in its behaviour on H.77 
affinity columns (Leckie, 1987, personal communication).
1.9. Aim of the present study
The control of renin release from human JG cells is, 
as yet, not clearly defined. As renin is the rate-limiting 
step in the renin-angiotensin system, it is of particular 
importance in the control of normal blood pressure and in 
some forms of hypertension. However, as was discussed in 
the preceding sections, the precise control mechanisms of 
renin release, at the second messenger level, are not 
firmly established.
The aim of the present study was, therefore, to 
investigate the control of human renin release, using a 
novel in vitro model system. Initially pharmacological 
agents, known to stimulate or inhibit renin release in vivo 
were tested in vitro and subsequently, a study of the 
possible second messengers involved in the responses, was 
carried out.
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CHAPTER 2
MATERIALS AND METHODS
2.1. Materials.
2.1.1. Biochemicals
All reagents used were 'AnalaR' grade. With the 
exceptions of the compounds listed below the reagents were 
obtained from BDH Chemicals Ltd., Poole, Dorset, U.K.
Tr is (hydroxymethyl) aminomethan2( crystallised) ethylene 
diamine tetra acetic acid (EDTA), bovine serum albumin 
(Fraction V) , human serum albumin (Fraction V) , soybean 
trypsin inhibitor (SBTI), sodium acetate, disodium 
phosphate, monopotassium phosphate, neomycin sulphate, 
guanosine S^S^cyclic monophosphate(Na+ salt), 3-isobutyl-l- 
methylxanthine (IBMX), polyoxyethylenesorbitan monolaurate 
(Tween 20), sodium deoxycholate, dithiothreitol, 
thimerosol, orthodianasidine hydrochloride, (- 
)isoproterenol HC1(isoprenaline), angiotensin II (human 
sequence), forskolin, pertussis toxin (islet activating 
protein), propanolol and dibutyryl cyclic AMP (dbcAMP) were 
purchased from Sigma Chemical Company Ltd., Poole, Dorset, 
U.K.
Dextran T7 0 was purchased from Pharmacia (Great 
Britain) Ltd., Hounslow, Middlesex.
Human ANP(l-28) was purchased from Bachem Ltd., 
Saffron Walden, Essex.
Glycine and trichloroacetic acid (TCA) were purchased 
from Fisons, Loughborough, Leicestershire.
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(lie5)-angiotensin I was obtained from Schwartz 
Bioresearch, Orangeburg, New York.
Asp1-NH2-Val5-angiotensin II ('Hypertensin1) was 
obtained from Ciba-Geigy, Horsham, Sussex.
Enalaprilat was obtained from Merck Sharp and Dohme 
(U.K.) Ltd.
2.1.2. Reagents for polyacrylamide gel electrophoresis. 
Acrylamide and N,N,N 1,N '-tetramethylethylenediamine
(TEMED) were purchased from Sigma Chemical Company Ltd., 
Poole, Dorset, U.K. N,N1-methylene-bis-acrylamide was 
obtained from Fisons (Electrophoresis reagent), 
Loughborough, Leicestershire. Pre-stained molecular mass 
markers were obtained from Bethesda Research Labs. 
Ammonium persulphate (AnalaR grade) was purchased from BDH 
Chemicals Ltd., Poole, Dorset, U.K.
2.1.3. Enzvmes
Trypsin (E.C. 3.4.21.4.) from bovine pancreas (type
III) was purchased from Sigma Chemical Company Ltd., Poole, 
Dorset, U.K. The specific activity of trypsin was 10,500 
units/mg protein where one B.A.E.E. unit will produce a 
A a 2 5 3 of 0.001 per min in 3.2 ml at pH 7.6 at 25°C (1 cm 
light path).
International Reference Standard Human Renin (MRC 
reagent 68/356) was obtained from the National Institute 
for Biological Standards and Control, Hampstead, London, 
U.K.
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2.1.4. Radiochemicals
[125I] Tyr4-Angiotensin I, Angiotensin II (5- L - isoleucine), 
[tvrosyl-^25I]- and Guanosine 3f,5*-cyclic phosphoric acid, 
[125i] 2 1-O-succinyl (iodosine methyl ester), , . ,
all 2,200 Ci/mmole, were
purchased from DuPont (U.K.) Ltd., Biotechnology Systems
Division, NEN Research Products, Hertfordshire.
Cyclic AMP assay kits containing [8-3H]Adenosine
3 1,5'-phosphate; 180 pmol/5/iCi were purchased from Amersham
International PLC, Aylesbury, Buckinghamshire.
2.1.5. Cell culture reagents/disposables
Tissue culture flasks (25 cm2, 75 cm2) (Nunc), Medium 
199, foetal calf serum, colcemid, glutamine and fungizone 
were purchased from Gibco BRL, Life Technologies Ltd., 
Paisley, Renfrewshire, Scotland.
Sterile flaskettes (Lab-Tek) were supplied by Flow 
Laboratories, Irvine, Scotland.
Penicillin/streptomycin solution, Earle*s balanced 
salt solution (without Ca2+ and Mg2+), trypsin (0.05% 
(v/v)/E.D.T.A. (0.02%) (v/v)) and Hank’s balanced salt
solution (HBSS) were obtained from Flow Laboratories Ltd., 
Irvine, Scotland.
Tissue culture flasks (125 cm2) were purchased from G. 
Bibby and Company, Stone, Staffordshire.
Cell scraper was purchased from Costar (Costar 
Corporation, Cambridge MA 02139) (suppliers: Northumbria
Biologicals Ltd., Northumberland, U.K.).
24 well tissue culture plates were obtained from 
Corning (Corning Glass Works, Corning, New York 14831).
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Sterile, 0.22/im (low protein binding) filter units 
were obtained from Millipore S.A., 67, Molsheim, France.
Microcentrifuge tubes were obtained from Scotlab, 
Bellshill, U.K. and were autoclaved for cell culture work 
using a pressure cooker (Prestige).
Sterile, disposable pipettes (10 ml) and sterile 
bijoux (7 ml) were purchased from Sterilin Ltd., Hounslow, 
U.K.
Sterile, disposable pastettes and sterile universals 
(30 ml) were purchased from Alpha Labs, Eastleigh, 
Hampshire.
Dimethylsulphoxide (DMSO) 1AnalaR' grade was obtained 
from BDH Chemicals Ltd., Poole, Dorset, U.K.
Sterile cryotubes for cell storage in liquid nitrogen 
were purchased from L.I.P., Shipley, West Yorkshire.
2.1.6. Miscellaneous materials
Glass microscope slides (frosted) (Chance) were 
supplied by Gallenkamp, Loughborough.
Filter papers were purchased from Whatman Ltd.
Liquid scintillator NE260 was obtained from N.E. 
Technology Ltd., Sighthill, Edinburgh, U.K.
Scintillation vials were obtained from L.I.P., 
Shipley, West Yorkshire.
2.2. General methods
2.2.1. Glassware
(i) All items of glassware were washed in solutions of 
the detergent Decon 75 (Decon Laboratories Ltd., Hove, 
U.K.), rinsed thoroughly with tap water, then distilled
57
water, and dried in an oven at 60°C.
(ii) Glass plates used for SDS/PAGE were thoroughly 
cleaned with alcohol (70% EtOH) before procedure (i).
2.2.2. Micropipetting
Solution volumes in the range 10/xl to 1ml were 
transferred reproducibly using Gilson pipettes (Gilson 
Medical Electronics (France) S.A., Villiers-Le-Bel, France) 
or using BCL 8000 automatic dispensers and BCL 8000 
syringes (Boehringer Mannheim, Lewes, East Sussex).
Graduated pipette tips were obtained from Alpha Labs, 
Eastleigh, Hampshire.
Volumes in the range 0.5/il to 50/xl were transferred 
accurately, using Hamilton microsyringes (BDH apparatus, 
BDH Ltd., Thornliebank, Glasgow, U.K.).
2.2.3. pH measurement
Measurements of pH were carried out using an Elcomatic 
Instruments Ltd. (Kent), model 7065 digital pH meter fitted 
with a combination electrode (Gallenkamp and Company Ltd., 
East Kilbride, Glasgow, U.K.). This apparatus was 
standardised regularly, using solutions of pH 7.0, pH 4.0 
and pH 9.2 prepared using buffer tablets (BDH Chemicals 
Ltd., Poole, Dorset, U.K.).
2.2.4. Centrifugation
Accelerations of up to lOOOg were obtained using a 
•Centra-7RI benchtop centrifuge (Damon/I.E.C. (U.K.) Ltd., 
Dunstable, Beds., U.K.). Accelerations of up to 100,000g 
were obtained using an LKB 2332 ULTROSPIN 85
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ultracentrifuge (LKB, Pharmacia House, Milton Keynes, 
Bucks.) fitted with a 45 Ti rotor (Beckman RIIC Ltd., 
Glenrothes, Fife, U.K.).
For small samples, accelerations of 10,000g were 
obtained using an MSE microcentrifuge 1Microcentaur', MSE 
Scientific Instruments, Crawley, West Sussex, U.K.
2.2.5. Measurement of protein concentration.
Protein concentration was measured by a modification 
of the method described by Lowry et al. (1951).
Stock solutions were prepared as follows:
Buffer A: 2% (w/v) Na2C03 (anhydrous) in 0.1M NaOH.
Buffer B^s 4% (w/v) sodium potassium tartrate
tetrahydrate in distilled water.
Buffer B2: 2% (w/v) CuS04.5H20 in distilled water.
Solution 1 was prepared by mixing Buffers A, B*^  and B2 
in the ratio 40:1:1, respectively, shortly before use. 1ml 
of solution 1 was added to 100/il of each of the samples (in 
lOmM Tris pH 7.4) to be assayed. These were then vortexed 
and left to stand for 10 minutes at room temperature. 
Next, 100/xl of solution 2 was added, the mixture vortexed 
immediately and allowed to stand for at least 30 minutes 
prior to determination of the absorbance at 700nm. Protein 
standards (0-25/xgs) were prepared using bovine serum 
albumin (Fraction V) dissolved in distilled water. 
Normally, 5 protein dilutions and 5 blanks of the 
appropriate buffer were taken for each sample.
2.2.6. Distilled water
Glass distilled water stored in glass containers was
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used in all experiments.
2.3. Cell culture.
2.3.1. General equipment.
The general items of equipment used in cell culture
with their suppliers are; 
Class II Microbiological 
Safety Cabinet
Heraeus C02incubator
Zeiss Invertoscope ID02
Electronic Coulter 
Counter (ZM)
Medical Air Technology Ltd., 
Denton,
Manchester.
McQuilken Ltd.,
Polmadie,
Glasgow.
Carl Zeiss 
(Oberkochen Ltd.)
Welwyn Garden City,
Herts., U.K.
Coulter Electronics Ltd., 
Luton,
Beds., U.K.
2.3.2. Routine culture
Nephroblastoma cells were cultured (Nunc flasks) in 
Medium 199, supplemented with 15% (v/v) foetal calf serum 
(FCS) , 2mM glutamine, 2.5/xg of fungizone/ml and 50 I.U. 
penicillin/50/xg of streptomycin/ml and used before the 10th 
subculture.
The cells were incubated in an atmosphere containing 
5% C02 at 37°C.
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2.3.3. Agonist experiments
2.3.3.(i) Short-term experiments
In short-term release experiments, cells were seeded 
and grown to confluence in 24-well tissue culture plates. 
At the end of a basal incubation period (18h) , the medium 
was removed and replaced with medium containing the 
appropriate agent, and the cells were incubated for 5 
hours.
Results of all short-term (5h) experiments are 
expressed as 1 active renin release, % change1. Active 
renin concentrations were determined for basal and 
experimental samples using the radioimmunoassay method of 
Millar et al., 1980 (Section 2.4.1.). These were then
corrected to rate of renin release per hour of cell culture 
and the percentage change was calculated.
2.3.3.(ii) 24 hour experiments
In 24 hour experiments, the protocol was identical to
2.3.3.(i) above except that the experiments were continued 
for up to 24 hours. The active renin concentrations were 
measured (Millar et al^ . , 1980) in the cell culture 
supernatants, at 24 hours.
Cells were harvested at 24 hours, using Earle*s 
balanced salt solution (without Ca2+ and Mg2+), followed by 
a 0.05% (v/v) trypsin/0.02% (v/v) EDTA solution.
The cell suspensions were used to determine cell 
number using a ZM electronic coulter counter.
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2.3.3.fiii). Long-term experiments
In long-term release and growth-rate experiments, 
cells were seeded and grown for 3-4 days. Medium was 
removed and replaced with medium containing the appropriate 
agent, and growth was continued for up to 12 days.
On day 3 of the experiments, the culture medium was 
changed, and at 3 day intervals (except in the 
isoprenaline/propanolol experiments (Section 3.2.3.)) 
samples were taken for active and total renin estimations 
(Section 2.4.1, 2.4.2).
Cells were harvested at intervals (Section 3.2.3) and 
counted, as previously described in Section 2.3.3.(ii).
In short-term release experiments, a minimum of four 
wells were used per agent and, in all other experiments, a 
minimum of 6 wells per agent were used. All experiments 
were carried out at least twice.
2.4. Assays
2.4.1. Renin assay
Renin concentration was measured using the method of 
Millar et a_l., 1980. This method is based on the
radioimmunoassay of the angiotensin I generated during the 
incubation of renin with excess ox renin substrate, using 
an antibody trapping technique.
The following stock reagents were prepared:
Buffer A: 3M-Tris/HCl(pH 6.9)/0.2M EDTA.
Buffer 50mM-Tris/HCl (pH 7.4)/5mM EDTA
0.5% (w/v) bovine serum albumin 
(Fraction V)/0.2% (w/v) neomycin sulphate.
62
Buffer C: 0.05M-Tris/HCl (pH 7.5)/0.18% (w/v)
human serum albumin (fraction V)/0.35%
(w/v) neomycin sulphate.
Dextran: 6.3g of charcoal and 0.125g of Dextran
coated
charcoal T-70 were suspended in 100 ml of Buffer B.
Assays were carried out by incubating 35/xl of cell 
culture medium at 37°C with 35/li1 of a pre-mixed solution 
consisting of ox renin substrate (Millar et al., 1980),
Buffer A and antiserum to angiotensin I, diluted in Buffer 
B (1:80 (v/v)). The ratio of the pre-mixed components was 
2:2:1 by volume. The enzyme reaction was terminated by 
adding 0.5mls of ice-cold Buffer B.
lOpg (5,000 - 10,000 cpm) of (125I) angiotensin I in 
50jil of Buffer C was added to the mixture and the 
radioimmunoassay was completed by further incubation at 4°C 
for 48 hours.
The separation of free and bound ligand was achieved 
by adding 200^1s of Dextran coated charcoal and immediately 
centrifuging the mixture for 10 minutes at l,000g and 4°C. 
The supernatant solution was removed by suction and the 
(125i)angiotensin I adsorbed to the charcoal pellet was 
then measured using a model NE 1612 gamma counter (Nuclear 
Enterprises Ltd., Sighthill, Edinburgh, U.K.).
Standard curves for angiotensin I were prepared by 
serial dilution of (lie5)angiotensin I in 35/ils of 7% human 
serum albumin (Fraction V) from l,000pg to 8pg angiotensin 
I per tube in duplicate. Tubes containing no angiotensin I
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*Data for intra- and inter-assay variation, recoveries 
of active renin across activation and assay steps, recovery 
of angiotensin I, detection limit of renin and 
radioimmunoassay sensitivity for angiotensin I have been 
reported previously (Miller et al., 1980).
were also included. 35#xl of the pre-mixed substrate 
solution was added to each tube and the standards were then 
treated in an identical manner to the unknown assay 
samples.
Originally, for each cell culture sample, the velocity 
of angiotensin I generation was determined using one timed 
incubation in duplicate and a zero time measurement. In 
practice, angiotensin I concentrations at zero time were 
undetectable and therefore only a 3 hour incubation was 
used.
The assay results were expressed in International 
Units of renin by comparison with the International 
Reference Standard Preparation of Human Renin (M.R.C. 
reagent 68/356).
One hundred /xUnits/ml of renin generated angiotensin I 
at a rate of 13.14ng/ml/hr in the above assay system.
2.4.2. Inactive renin
Inactive renin was assayed by measuring the increase 
in renin activity produced by the treatment of samples with 
trypsin.
The activation of inactive renin was carried out using 
a modification of the method, as described by Millar et 
al., 1980.
The following stock solutions were prepared:
Trypsin solution: Crystalline trypsin 10,500 B.A.E.E.
Units/mg protein (Section 2.1.3.), 
was dissolved in ImM-HCl to a final 
concentration of lOmgs/ml. Fresh
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solutions of the enzyme were 
prepared each day. The crystalline 
enzyme was stored at -20°C with 
dessicant.
SBTI solution : Soybean trypsin inhibitor was
dissolved in ImM HC1 to a final 
concentration of 20mgs/ml.
Usually 500/il of cell culture supernatant was 
activated by treatment with 50/xls of trypsin solution and 
the solution was incubated for 5 minutes at 4°C. The 
reaction was stopped by adding 50/xl of SBTI solution and 
the renin concentration was then measured, as described in 
Section 2.4.1. Often, trypsin activated samples required 
dilution (in Buffer B - see Section 2.4.1.), prior to renin 
concentration measurement. Initially, zero time samples 
were included in the renin assay to allow for angiotensin I 
immunoreactive material generated during the incubation of 
unknown samples with trypsin. As angiotensin I 
concentrations were undetectable, this step was omitted 
from subsequent assays.
The renin concentration measured after trypsin- 
activation was defined as the total renin concentration. 
The active renin concentration was measured after an 
identical incubation at 4°C, except that the samples had 
not been trypsin-activated. The inactive renin 
concentration was calculated as the difference between the
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total renin concentration and the active renin 
*concentration.
2.4.3. Angiotensin II (Ajj) assay
The preparation of antisera and the radioimmunoassay 
for angiotensin II (Ajj) were performed, essentially, using 
the methods as described by Morton et al. 1976? Morton and 
Webb (1985) (except that Sep-pak extraction was not 
carried out).
For the radioimmunoassay of Aj j, the following stock 
reagent was prepared:
Buffer A: 0.05M-Tris/HCl (pH 7.5)/0.18% (w/v) human 
serum albumin (fraction V)/0.35% (w/v) 
neomycin sulphate.
Briefly, Ajj antiserum (100/il at 1:30,000) was mxied 
with standard (100/xl of 0-100pg) or unknown (100?xl) and 
125I-labelled AI3- (50/xl, 2.5pg) in Buffer A for 18h at 4°C.
Bound label was separated from free using dextran- 
coated charcoal.
2.4.4. cGMP assay
At the end of agonist experiments, typically 0.25mls 
of cell culture supernatant was extracted into 1ml of 
chilled methanol (100%) (Williams, B.C., 1988, personal
communication). The purpose of the chilled methanol is to 
precipitate out protein and to effectively extract cGMP and 
also, to concentrate the sample. The extraction mixture 
was centrifuged, at lOOOg for 10 mins at 4°C, to pellet out 
the protein. The supernatant was carefully removed and the 
pellet was washed with a further 0.5mls of chilled methanol
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(100%) . The mixture was once again, centrifuged and the 
supernatants were pooled for each sample.
For radioimmunoassay of cGMP, the following stock 
reagents were prepared:
Buffer A: 0.05M-Tris pH 7.5 containing 0.5mmol/l 
3-isobutyl-l-methyl xanthine (IBMX).
Buffer B: 50mM-Tris pH 7.5.
Buffer C: 50mmol/l sodium acetate, pH 6.2.
The extracts were dried down under compressed air and 
reconstituted in Buffer A. The radioimmunoassay for cGMP 
was performed using the method as described by Lyall et 
al.. 1988b.
Briefly, cGMP antiserum (100/xl at 1:20,000, in Buffer 
B) was mixed with standard (100/xl of 0-5pmol/ml or 0- 
2pmol/ml in Buffer B) or unknown (100/xl) and 125I-labelled 
cGMP (50/il? 2pg) in Buffer C for 18 hours at 4°C.
Bound label was separated from free using dextran- 
coated charcoal.
2.4.5. cAMP assay
At the end of agonist experiments, incubations were 
terminated, after removal of the medium, by the addition of 
lml chilled ethanol (100%) (Friedl et al., 1985? Williams, 
B.C., 1988, personal communication).
This was immediately spun, at lOOOg for 10 mins at 
4°C. The supernatant was carefully removed and the pellet 
was re-extracted/washed with a further 0.5mls of chilled 
ethanol (100%). This supernatant was pooled with the first
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and the extract was dried under compressed air. The dried 
extracts were reconstituted in 0.05M Tris pH 7.5/4mM EDTA 
containing 100/iM IBMX.
Intracellular cAMP concentrations were then measured 
using a cAMP radioimmunoassay (Amersham International PLC).
This method is based on the competition between 
unlabelled cAMP and a fixed quantity of the 3H-labelled 
cAMP for binding to a cAMP-binding protein.
2.5. Membrane preparations/immunological analysis.
2.5.1. Nephroblastoma cell membrane preparations
Nephroblastoma cells, which had been maintained in 
culture, up to the 7 th subculture (P7), were grown to 
confluence in 125cm2 tissue culture flasks. Confluent 
flasks were harvested by scraping the cells from the flask 
surface, using a cell scraper (Costar) into, approximately 
40mls of HBSS (Flow Laboratories) . Cell membranes were 
prepared, using a modification of the procedure as 
described by Jakobs et al., 1982.
The following stock buffers were prepared:
Buffer A: lOmM-Tris/lmM EDTA pH 7.5.
Buffer B: lOmM-Tris pH 7.4.
The protocol used was as follows:
1. Cells were centrifuged at l,000g for 5 mins, at 4°C, to 
pellet the cells.
2. The pellet was resuspended in approximately 5mls of 
Buffer A.
3. The re-suspended pellet was homogenized using a small 
polytron (Polytron PT2 05) (Kinematica, GmbH,
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Switzerland), setting *6* for 2 x 12 seconds.
(The preparation was kept on ice throughout this 
procedure).
4. A clearing spin, in which the suspension was centrifuged 
at lOOOg for 5 mins at 4°C, was carried out to remove 
any unbroken cells.
5. The suspension was ultracentrifuged at 35,000g in an LKB 
2332 ultrospin 85 ultracentrifuge, fitted with a 45 Ti 
rotor (Beckman RIIC Ltd.) for 1 hour at 4°C, in order to 
collect a crude membrane pellet.
6. The crude membrane pellet was then resuspended in 
approximately, 3mls of Buffer B and then hand 
homogenized, using a small Teflon/glass homogenizer 
(about 10 strokes) to form a homogeneous membrane 
suspension.
The protein concentration of the cell membrane 
preparation was determined, using the method as previously 
detailed in Section 2.2.5. The membranes were then 
aliquoted into suitable fractions, in practice about 260/xls 
(depending on protein concentration), and stored at -70°C, 
until required for use. Membranes were found to remain 
stable, in these conditions, for at least 3 months.
2.5.2. SPS/PAGE and immunoblotting
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS/PAGE) was performed according to 
Laemmli, 1970.
Standard amounts of membranes from cultured
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nephroblastoma cells; human platelets? cultured vascular 
smooth muscle cells (Jakobs et al., 1982); rat (kidney
heart and adipocytes) (Sharma et aJL. , 1982); and from
cerebral cortices of rat brain (McKenzie et al., 1988) were 
precipitated using trichloroacetic acid (TCA)/deoxycholate 
(Bensadoun and Weinstein, 1976). These, along with pre­
stained molecular mass markers (Bethesda Research Labs) 
were resolved by SDS/PAGE [10% (w/v) acrylamide], in
vertical slab gels overnight at 40-50V.
Proteins were transferred, using an Electroblotting 
Unit (LKB BROMMA 2005 Transphor Electroblotting Unit) with 
constant current (100V) for 1\ hours, to nitrocellulose 
(Schleicher and Schuell, Dassel, W. Germany). The 
nitrocellulose was then blocked for 2 hours at 37°C with 3% 
(w/v) skimmed milk (Marvel) in Tris-buffered saline (TBS) 
(20mM Tris/HCl, pH 7.5/500mM-NaCl). This was removed and
the blots were washed extensively with distilled water.
Primary antiserum (1:200 dilution) (which was kindly 
provided by Dr. G. Milligan (Section 7.2.)) in 1% 
gelatin/TBS was then added, and left overnight. The 
primary antiserum was then removed and the blot was washed 
extensively with distilled water followed by washes with 
TBS containing 0.05% (v/v) Tween-20 (TTBS) and then TBS.
Secondary antiserum (donkey anti-rabbit IgG coupled to 
horseradish peroxidase) (Scottish Antibody Production Unit, 
Wishaw, Scotland) (1:100 dilution) in 1% gelatin/TBS was 
added and left for 3 hours. Removal of the secondary 
antiserum was followed by the same series of extensive
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washes of the nitrocellulose as detailed following removal 
of the primary antiserum. Orthodianasidine hydrochloride 
was employed as the substrate for detection of the antibody 
complex.
2.6. Immunocvtochemical studies
Nephroblastoma cells (no older than the 10th 
subculture) were grown in flaskettes on glass coverslips. 
When the slides were confluent, as judged by light 
microscopy, the slides were fixed and immunostained with 
antisera to vimentin and a range of epithelial cell markers 
such as cytokeratins, epithelial membrane antigen (EMA) 
(Polak and Van Noorden, 1986) . Also the cells were 
immunostained using two renin antisera, as described 
previously by Lindop et al. (1984).
2.7. Electron Microscopy
This was carried out by the Electron Microscopy Unit, 
Department of Pathology, Western Infirmary, Glasgow, using 
routine methods.
Briefly, cells were fixed in 2% glutaraldehyde 
buffered with Sorenson's phosphate buffer, pH 7.38 and 
post-fixed with osmium tetroxide. Following embedding in 
araldite, sections were cut employing an LKB Ultratome III, 
double stained with uranyl acetate and lead citrate then 
viewed in a Philips CM10 microscope.
2.8. Karvotvpincr
Young nephroblastoma cells which were actively 
dividing in culture (typically at subculture 3 or 4) were
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used to determine the karyotype.
2.8.1. Preparation of chromosome spreads
At least 24 hours after subculturing, cells were 
treated with colcemid (as an arresting agent), for 2-3 
hours. The cells were then harvested using
trypsin/E.D.T.A. and treated with 37.5mM KC1 (hypotonic 
solution) at 37°C. The cells were then centrifuged and 
fixed in three changes of 1:3 (v/v) acetic acid:methanol.
2.8.2. Staining techniques
2.8.2.(i) Solid Staining
The following stock solutions were required:
Solution A: 3g of Leishman's powder in 2 litres of
(Leishman's
stain) methanol. Filter using Whatman filter paper.
Solution B: 1 tablet of Gurr pH 6.8 buffer in 1 litre
(Gurr1s
buffer) of distilled water.
The method used for solid staining was:
(i) Mix 1:3 (v/v) Solution A : Solution B.
(ii) Apply this mixture to the slide for a few minutes.
(iii) Wash off solution with tap water and dry slide on 
hotplate (or carefully blot dry with paper towel).
2.8.2.(ii) G-bandina
The following stock solutions were required:
Solution A: 0.067M Na2HP04? 0.067M KH2P04 in 1 litre of
(Sdrenson's
Buffer) distilled water.
Solution B: 1.2g of Difco powdered trypsin in 1 litre of
(Trypsin
Solution) Solution A.
For G-banding, slides should be faged' by hardening at 
80°C for 2 hours and then banded, using a modification of
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the method as described by Gallimore and Richardson (1973). 
Briefly?
(i) The slide is flooded with solution B for 5-25 
seconds (timing varies).
(ii) Solution B is then washed off using Solution A.
(iii) Slides are then stained as for solid staining.
2.9. Statistical analysis
All results were compared by analysis of variance 
using Newman-Keuls multiple range test where appropriate.
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CHAPTER 3
The effects of /?-adrenergic agonists on renin release and 
cell growth.
3.1. Introduction
Innervation of the renal arterioles and the JG 
apparatus was first observed in 1952 when De Muylder 
identified nerves travelling to the afferent renal 
arterioles in the region of the granular JG cells. A 
decade later, Barajas (1964) examined the innervation of 
the JG apparatus by electron microscopy and found that non­
myelinated nerve fibres, possibly noradrenergic, were 
associated with the afferent and efferent arterioles in 
monkeys and rats. In the ensuing years, other researchers 
(Biava and West, 1966) have confirmed that the JG cells of 
rats, dogs and humans are innervated by sympathetic fibres.
Vander (1965) was the first to show that direct 
stimulation of the renal nerves or intravenous (i.v.) 
infusion of catecholamines in anaesthetized dogs caused 
stimulation of renin release. In man, the renal nerves are 
involved in the renin release which occurs after upright 
tilting, exercise, cold stress or i.v. frusemide (Sonkodi 
et al. , 1982). jS-Adrenergic receptor blockade with
propanolol diminishes, but does not abolish the rise in 
plasma renin concentration and plasma Ajj concentration, on 
upright tilting or frusemide injection. These results 
suggest that the renal nerves probably control renin 
secretion.
Catecholamines exert their effects through stimulation
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of a- and /3-adrenergic receptors. Renal nerve stimulation 
increased the release of renin via the activation of /?- 
adrenergic receptors (Osborn et jil., 1981). Direct
stimulation of the renal ^-adrenergic receptors with 
isoprenaline stimulates renin release from kidney slices 
(Capponi and Vallotton, 1976) . Also the rate of renin 
release from isolated rat glomeruli, superfused in vitro, 
is stimulated when the preparation is exposed to 
noradrenaline, adrenaline or isoprenaline (Morris et al., 
1976).
The intracellular signal of the /3-adrenergic pathway 
is often cAMP, but it is uncertain whether cAMP is the 
final signal which couples ^-stimulation with renin 
secretion.
In the present study, therefore, experiments were 
carried out to investigate the mechanisms involved in
/3-adrenergic-controlled renin release.
It was first necessary to establish if /3-agonists 
would stimulate renin release in this model.
It seemed possible that the long-term control of renin 
release may occur through additional or different 
mechanisms to the short-term. Thus, experiments were 
carried out using different times of exposure to /3- 
agonists.
3.2. /3-Adreneraic agonist experiments
3.2.1. Short-term release experiments
Cells were seeded at 2 x 104 cells/ml and grown to
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confluence (Section 2.3.3. (i)). At the end of the basal 
incubation period, the medium was removed and replaced with 
medium containing isoprenaline, forskolin or dbcAMP at 
concentrations ranging from O.lmM to 1/iM, and the cells 
were incubated for 5 hours. The concentration of active 
renin released at 5 hours was measured as detailed in 
Section 2.3.3.(i).
3.2.2. 24 hour release/growth rate experiments
24 hour experiments were carried out as detailed in 
Section 2.3.3.(ii). At the end of the basal incubation 
period, medium was removed and replaced with medium 
containing isoprenaline (1/xM) , forskolin (O.lmM) or dbcAMP 
(O.lmM). Active renin levels were measured, at 24 hours, 
and cells harvested and counted as detailed in Section
2.3.3.(ii).
3.2.3. Long-term release and growth rate experiments
In long-term release and growth-rate experiments, 
cells were seeded at a density of 2 x 105 cells/ml (Figures
3.2, 3.3) or 3 x 104 cells/ml (Figure 3.4) (1 ml/well in
each experiment) , and grown for 3-4 days (Section
2.3.3.(iii)). Medium was removed and replaced with medium 
containing isoprenaline (ljxM) alone, isoprenaline (1/xM) and 
propanolol (1/xM), propanolol (1/xM) alone, forskolin (O.lmM) 
or dbcAMP (O.lmM) and growth was continued for up to 12 
days.
On day 3 of the experiments, the culture medium was 
changed and at 3 day intervals (except in the isoprenaline 
and propanolol experiments, where intervals were 3 and 4
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days) samples were taken for active and (in the
isoprenaline experiments (Figure 3.2)) total renin 
estimations (Sections 2.4.1., 2.4.2.). At 6 day intervals 
(Figure 3.2), on day 6 and day 10 (Figure 3.3) and on day 6 
and day 9 (Figure 3.4) cells were harvested and counted 
(Section 2.3.3.(ii)).
3.3 Results and discussion
3.3.1. Short-term experiments
In short-term release experiments (5h), active renin 
release was stimulated by O.lmM- but not by 1/xM - 
isoprenaline (Figure 3.1.a). Stimulation of renin 
secretion also occurred with O.OlmM forskolin or O.lmM
dbcAMP (P < 0.01) (Figure 3.1.b).
These results confirm that renin secretion is 
stimulated by 0-adrenergic receptor agonists and by agents 
(forskolin and dbcAMP) which raise intracellular cAMP 
concentration.
3.3.2. 24 hour experiments
In 24 hour experiments, the levels of active renin 
release (Table 3.1) were significantly stimulated by l^M
isoprenaline (P < 0.01), O.lmM forskolin (P < 0.01) and
O.lmM dbcAMP (P < 0.01).
Cell counts done in one set of the experiments showed
that cell growth was stimulated by 1/iM isoprenaline (P <
0.01) and O.lmM dbcAMP (P < 0.01) at 24 hours.
The increase in cell growth, noted in this experiment
was an unexpected finding, and suggests that renin
production may be stimulated by different mechanisms during
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Figure 3.1: Short-term (5h) exposure to (a) Isoprenaline 
(ISO) (O.lmM , 1/iM) and (b) dbcAMP (O.lmM, 
1/iM) , forskolin (O.OlmM).
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Table 3.1
Active renin concentrations in cell culture supernatants at 
24 h.
Results are expressed as mean + S.E.M. (n - 6).
Renin activity (/xUnits/ml)
Control Agent P value
isoprenaline (1/iM) 6.8+0.4 14.3+0.6 <0.01
dbcAMP (O.lmM) 9.4+0.4 11.5+0.3 <0.01
forskolin (O.lmM) 6.5+0.4 14.0+0.5 <0.01
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short-term and long-term exposure to /3-agonists ". This 
was further investigated in long-term experiments in which 
the cells were grown in the presence of isoprenaline and 
related agents for up to 12 days.
The specificity of the isoprenaline response was 
tested by using a /3-adrenergic receptor antagonist; 
propanolol.
3.3.3. Long-term experiments
3.3.3.(i). Isoprenaline
After 9 days exposure to 1/xM isoprenaline (Figure
3.2.a(i)), a significant stimulation of both active (P < 
0.01) and total (P < 0.01) (Figure 3.2.a(ii)) renin release 
was observed. This occurred in three separate experiments. 
Cell number was significantly increased after 12 days 
exposure to 1/xM isoprenaline in all three experiments (P < 
0.025) (Figure 3.2.b). In one experiment, the increased 
cell growth was significant by day 6 (P < 0.01) (results 
not shown).
When the increased renin secretion was related to cell 
number (Figure 3.2.c), it was found that the increase in 
renin release per cell was not significantly different 
between the isoprenaline-treated cells and controls, in all 
three experiments. Therefore, the increase in renin 
secretion after long-term treatment with 1/xM isoprenaline, 
can be accounted for by stimulated cell growth.
The long-term action of isoprenaline on renin 
secretion and nephroblastoma cell growth was blocked by the
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Figure 3.2: Long-term action of isoprenaline (1/zM) on 
(a)(i) active renin release and (b) cell 
growth (where IP = isoprenaline)•
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Figure 3.2.(a)(ii): Long-term action of isoprenaline
(lMM) on total renin release.
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addition of the /3-blocking agent, propanolol (1 /iM) (Figures
3.3.a,b). This indicates that isoprenaline causes its 
effects by a direct, specific action on /3-adrenergic 
receptors. There was also observed to be a slight
stimulation of renin release, in response to long-term 
treatment with 1/iM propanolol alone. This is probably
because, at high doses, the /3-adrenoceptor antagonist may 
have a partial agonist effect.
3.3.3.(ii). Forskolin. dbcAMP
Active renin release was stimulated by long-term 
exposure to O.lmM forskolin at day 6 (P < 0.05) and O.lmM 
dbcAMP also caused stimulation of active renin release by 
day 9 (P < 0.05) (Figure 3.4. a). Cell number was
significantly increased by O.lmM forskolin at day 9 (P < 
0.05) and O.lmM dbcAMP at day 6 (P < 0.01) (Figure 3.4.b.).
When renin secretion was related to cell number 
(Figure 3.4.C.), it was found that the increase in active 
renin secretion caused by O.lmM dbcAMP could also be 
accounted for by an increase in cell growth. However, the 
increase in active renin secretion caused by O.lmM
forskolin was caused by an increase in renin secretion per 
cell. This was observed in three separate forskolin 
experiments.
3.4. Discussion
The results of the present study show that O.lmM 
isoprenaline, O.OlmM forskolin and O.lmM dbcAMP (P < 0.01) 
stimulate renin secretion from cultured nephroblastoma 
cells at 5 hours, a time within the cell cycle. The
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Figure 3.3: The effect of l^ iM propanolol on (a)
isoprenaline-stimulated renin release 
and (b) cell growth.
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Figure 3.4: Long-term action of O.lmM forskolin and O.lmM 
dbcAMP on (a) active renin release and (b) 
cell growth.
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Figure 3.4. (c)> Renin release per cell number
pU/106celis
Time 
Day 9
Control Forskolin(O.lmM) dbcAMP(O.lmM)
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P<0.01 P>0.05
N.S.D.
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increased secretion may be due to either an increase in 
exocytosis alone, or to increased renin synthesis, gene 
expression and exocytosis. In the normal JG cell, renin is 
stored in granules and the immediate response to a stimulus 
is likely to be an increase in the rate of exocytosis. 
However, for secretion to be maintained, an increase in the 
rate of renin synthesis must eventually occur.
Isoprenaline-stimulated renin release from 
nephroblastoma cells has been shown to be a /3-receptor- 
mediated event (Section 3.3.3.(i)). In contrast, the 
diterpene compound, forskolin, is a direct (receptor- 
independent) stimulant of the catalytic subunit of 
adenylate cyclase (Seamon and Daly, 1981) and, therefore, 
by-passes the /3-receptor.
The increased renin secretion after long-term exposure 
to isoprenaline mainly occurs through increased cell 
growth. In contrast, forskolin causes an increase in renin 
release per cell. The increased cell growth appears to be 
mediated via adenylate cyclase, since dbcAMP also 
stimulates cell growth. However, forskolin was not as 
effective (at increasing cell number) as isoprenaline or 
dbcAMP in this system in vitro.
At this stage, it can be concluded that stimulated 
nephroblastoma cell growth, is a /3-receptor-mediated event, 
involving adenylate cyclase stimulation and increased 
concentration of intracellular cAMP. Also, it can 
be tentatively suggested that forskolin may have an
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additional role in these cells, different to those of 
isoprenaline and dbcAMP, which may render it ineffective in 
stimulating cell growth.
It is known that forskolin acts by directly activating 
the catalytic subunit of adenylate cyclase. However, there 
have been recent reports (Laurenza et aJ. , 1989) that
forskolin has other actions (such as inhibition of membrane 
transport proteins) which do not involve production of 
cAMP.
The intracellular mechanisms whereby these agents 
(i.e. isoprenaline, dbcAMP and forskolin) mediate their 
effects was investigated, in subsequent experiments.
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CHAPTER 4
The effect of ANP on basal and /7-adrenergic-stimulated 
renin release and cell growth.
4.1. Introduction
Atrial natriuretic peptides (ANP) from mammalian atria 
have been purified, sequenced and characterized (Currie et 
al., 1984; Kangawa and Matsuo, 1984). Specific receptors 
for ANP occur in diverse tissues such as lung (Kuno et al.. 
1986), adrenal (Meloche et al., 1986), kidney (Yip et al. . 
1985) and smooth muscle (Schenk et al., 1985; Hirata et
al., 1984).
Two major effects of ANP on renal function have been 
described, namely the enhancement of sodium and water 
excretion (c.f. De Bold et al., 1981 and Maack et al.,
1985) and the suppression of renin release (Maack et al., 
1984; Burnett et al., 1984; Anderson et al., 1987).
The diversity of receptor distribution and biological 
effects suggests that the cellular mechanism of ANP action 
may involve different receptors and different intracellular 
second messenger cascade systems.
In addition to cGMP (Section 1.5.3.), ANP has also 
been recognized to operate through cAMP, because ANP has 
been demonstrated to be an inhibitor of adenylate cyclase 
in certain tissues (Anand-Srivastava et al., 1984; Anand-
Srivastava et al., 1985). Also, Ishikawa et al. (1985),
showed that ANP diminished the stimulatory effect of 
arginine vasopressin (AVP) on cellular cAMP production from 
rat cultured collecting tubule cells.
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Receptors for many hormones and growth factors which 
are able to modulate the rate of production of second 
messengers, such as cAMP are dependent upon the 
intermediate activation of one or more, G-proteins. Each 
G-protein is a heterotrimer, in which distinct a subunits 
share a common population of /?/& subunits.
Initial identification of G-protein a-subunits were 
based on the known ability of toxins elaborated by Vibrio 
cholerae and Bordatella pertussis to modulate the adenylate 
cyclase cascade. The observation that pertussis toxin was 
able to catalyse ADP-ribosylation of the inhibitory G- 
protein of the adenylate cyclase cascade and consequently 
attenuate receptor-mediated inhibition of adenylate cyclase 
(Katada and Ui, 1981), provided a tool with which to 
identify G^. ADP-ribosylation occurs at a cysteine residue 
located four amino-acids from the C-terminus and the 
modification appears to be sufficient to prevent productive 
interactions between receptors and G^.
Therefore, pertussis toxin is a useful agent, which 
can be used to investigate whether or not a hormone causes 
G^-mediated inhibition of adenylate cyclase.
The mechanism by which ANP inhibits renal renin 
release is, as yet, a matter of debate (Maack et al., 1985) 
and the exact mechanisms underlying the cellular and 
molecular action of ANP are still unknown.
Therefore, in the present study, using the 
nephroblastoma cells as a model in vitro, it was decided to
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examine whether or not ANP inhibits renal renin release in 
vivo by a direct action on the JG cell and, if so, which 
second messengers were involved.
4.2. The effect of ANP on basal renin release
4.2.1. Short-term ANP experiments
Cells were seeded and grown to confluence (Section
2.3.1.(i)). At the end of the basal incubation period, the 
medium was removed and replaced with medium containing 1/xM 
ANP and the cells were incubated for 5 hours.
Also, in order to test for the presence of a pertussis 
toxin-sensitive G-protein, short-term experiments were 
carried out in which the cells were treated with medium 
containing 1/iM ANP alone? 1/xM ANP and lOOngs/ml pertussis 
toxin, and lOOngs/ml pertussis toxin for 5 hours.
The concentration of active renin released at 5 hours 
was measured (Section 2.3.3.(i), 2.4.1).
4.2.2. 24 hour release/growth rate experiments
24 hour experiments were carried out as detailed in 
Section 2.3.3.(ii). At the end of the basal incubation 
period, the medium was removed and replaced with medium 
containing a range of doses (lpM to 1/xM) of ANP.
In order to determine whether ANP had any effect on 
isoprenaline, forskolin or dbcAMP-stimulated renin release, 
cells were grown in medium containing 1/xM isoprenaline,
O.lmM forskolin or O.lmM dbcAMP, in the presence or absence
of 1/xM ANP, for 24 hours.
Active renin levels were measured at 24 hours and
cells harvested and counted (Section 2.3.3.(ii)).
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4.3. Results and discussion
4.3.1. Short-term experiments
ANP (1/xM) was found to inhibit active renin release in 
short-term (5h) experiments (P < 0.01) (Figure 4.1). This 
inhibition was released by the presence of lOOngs/ml 
pertussis toxin (Figure 4.2). This means that short-term 
ANP-mediated inhibition of active renin release is possibly 
mediated by a pertussis toxin-sensitive G-protein.
4.3.2. 24 hour experiments
4.3.2.(i). Dose-resoonse to ANP
The dose-response experiment which was carried out for 
24 hours showed that ANP inhibited active renin release to 
60% of control values at the optimal dose of 1/xM (results 
not shown).
4.3.2.(ii). The effect of ANP on isoprenaline-induced renin 
release and cell growth
Active renin release was significantly (P < 0.01)
stimulated by 1/xM isoprenaline at 24 hours (Figure 4.3.a). 
This confirms our previous results (Section 3.3.2.). 
Isoprenaline-induced renin release was significantly 
attenuated by 1/iM ANP (P < 0.01) (Figure 4.3.a.). Cell
number was significantly increased by 1/xM isoprenaline 
treatment for 24 hours (P < 0.01) (Figure 4.3.b.), and this 
was significantly reduced (P < 0.01) by 1/xM ANP.
Table 4.3.C shows renin release related to cell 
number.. As described in Section 3.3.2., treatment with 1/xM 
isoprenaline apparently increased renin secretion at 24 
hours, but this was due to an increase in cell number.
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Figure 4.i:Short-term (5h) exposure to 1pM ANP
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Figure 4.2: The effect of pertussis-toxin (lOOngs/ml) 
on ANP-inhibited renin release.
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Figure 4.3:
The effect of ANP on (a) isoprenaline- stimulated
renin release and (b) ceil growth at 24h
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Thus renin release per cell remained the same.
Treatment with 1/liM ANP for 24 hours lowered renin 
release by decreasing cell number. Therefore, the response 
at 24 hours was due mainly to an effect on cell growth.
4.3.2. (iii). The effect of ANP on dbcAMP-induced renin 
release and cell growth
Active renin release (Figure 4.4.a) was significantly 
stimulated (P < 0.01) by 24 hour treatment with dbcAMP 
(O.lmM). ANP (1/iM) significantly attenuated dbcAMP- 
stimulated renin release (P < 0.01). Cell growth was
significantly increased after 24 hour treatment with O.lmM 
dbcAMP (P < 0.01) (Figure 4.4.b). This was reduced
slightly by the presence of 1/xM ANP but the difference was 
non-significant. 1/xM ANP alone, did not inhibit cell 
growth.
Table 4.4.C. shows renin release related to cell 
number. As described in Chapter 3, treatment with O.lmM 
dbcAMP caused an increase in renin secretion at 24 hours. 
This increase in renin release was due to an increase in 
cell number and the rate of renin release per cell remained 
the same.
Treatment with 1/zM ANP for 24 hours, lowered renin 
release through a suppression of dbcAMP-stimulated cell 
growth, although the effect was not as marked as that of 
ANP on isoprenaline-stimulated cell growth. Renin release 
per cell number at 24 hours was not significantly different 
and so ANP must reduce dbcAMP stimulated renin release by 
an effect on cell growth.
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Figure 4.4:
The effect of ANP on (a) dbcAMP-stlmulated renin
release and (b) cell growth at 24h
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4.3.2.(iv). The effect of ANP on forskolin-induced renin 
release.
Active renin release was significantly stimulated by 
O.lmM forskolin (P < 0.01) at 24 hours (Figure 4.5.a). 1/xM 
ANP treatment for 24 hours, significantly reduced 
forskolin-stimulated renin release (P < 0.01). However, in 
contrast to that found with isoprenaline and dbcAMP, O.lmM 
forskolin had no effect on cell growth at 24 hours (Figure
4.5.b.).
Table 4.5.c. shows renin release related to cell 
number. As previously mentioned (Section 3.3.2.), 
treatment with O.lmM forskolin caused an increase in renin 
release, but did not apparently cause an increase in cell 
growth, at 24 hours.
Treatment with ljxM ANP for 24 hours lowered renin 
release by decreasing the rate of renin release per cell. 
Thus, in contrast to that found with 1/iM isoprenaline and 
O.lmM dbcAMP, the response to O.lmM forskolin at 24 hours, 
was due to an effect on renin release per cell.
4.4. Conclusions
From the present study, it can be concluded that ANP 
inhibits basal renin release from human cultured 
nephroblastoma cells, possibly via a pertussis toxin- 
sensitive G-protein and inhibition of adenylate cyclase 
activity.
ANP ( 1/liM) also antagonises /3-adrenergic stimulated 
renin release and it does so by either attentuation of /S- 
stimulated cell growth (in the case of isoprenaline,
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Figure 4.5:
The effect of ANP on (a) forskolin-stlmulated renin
release and (b) cell growth at 24h
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dbcAMP) or by reduction of /^-stimulated renin release 
per cell (as in the case of forskolin).
It was decided to investigate in detail the 
intracellular second messenger responses to these agents, 
in order to try and decipher their interactions, which 
could account for the responses observed so far.
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CHAPTER 5
The role of second messengers in the control of renin 
release.
5.1 Introduction
The role of second messengers involved in the control 
of renin release, is not well established (Section 1.6). 
Using the nephroblastoma cells as a model in vitro, it has 
been determined that active renin release is stimulated by 
isoprenaline, dbcAMP and forskolin on a short-term basis, 
which is probably mediated by adenylate cyclase.
However, stimulation at 24 hours, revealed a 
difference in the mechanisms of isoprenaline (and dbcAMP) 
and forskolin. Isoprenaline (and dbcAMP) caused a 
stimulation of cell growth at 24 hours, in contrast to 
forskolin which acted mainly by increasing renin release 
per cell. Furthermore, this effect was maintained in the 
long-term experiments (up to 12 days) and was specific (in 
the case of isoprenaline).
Therefore, it can be concluded that isoprenaline and 
forskolin stimulate renin release by different mechanisms 
and this is first evident at 24 hours.
ANP is a peptide hormone which is becoming 
increasingly important in the control of renin release. 
The present study has shown that ANP inhibits basal renin 
release from cultured nephroblastoma cells directly, over a 
period of 5 hours.
The results of 24 hour experiments showed that ANP
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(1/xM) significantly attenuated 0-adrenergic-stimulated 
renin release. This was specifically (in the case of 
isoprenaline and dbcAMP) by blocking the increase in cell 
growth.
As the interactions of ANP with /?-stimulated renin 
release and cell growth were very interesting, it was 
decided to investigate the second messenger responses in 
detail.
5.2. Second messenger time course experiments
Cells were seeded and grown to confluence (Section
2.3.3.(i)). At the end of the basal incubation period, the 
medium was removed and replaced with medium containing; 
isoprenaline (1/xM) alone, ANP (1/iM) alone, isoprenaline 
(1/iM) and ANP (ImM) . All medium contained the 
phosphodiesterase inhibitor; 3-isobutyl-l-methylxanthine 
(IBMX), at 0.5mM.
Identical experiments were set up in which the cells 
were treated with forskolin (O.lmM) alone, ANP (1/xM) alone, 
or forskolin (O.lmM) and ANP(1/*M). Again, all medium 
contained IBMX at 0.5mM.
It was decided to look at cGMP and cAMP concentrations 
in each well, in response to agents.
The extracellular appearance of cGMP is used as a 
marker of the biological activity of ANP (Hamet et al. . 
1986; Lewis et al., 1988).
Therefore, it was decided that extracellular cGMP 
concentrations (Section 2.4.5.), intracellular cAMP 
concentrations (Section 2.4.6) as well as active renin
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concentrations (Section 2.3.3.(i)) should be measured at 
the following times: basal, 1 minute, 5 minutes, 1 hour and
6 hours after the addition of the agents.
5.3. Results and discussion
5.3.1. Comparison of second messenger responses in medium 
with and without phosphodiesterase inhibitor
Initial experiments were carried out, in order to look 
at second messenger levels in response to treatment of the
cells (for up to 24 hours) with individual agonists.
Intracellular cAMP concentrations were significantly 
raised in response to administration of O.lmM forskolin, at 
5 mins (P < 0.05) and in response to O.lmM dbcAMP at 6 
hours (P < 0.05). 1/xM ANP had no significant effect on 
intracellular cAMP concentrations (results not shown).
However, lpiM ANP caused stimulation of extracellular 
cGMP concentrations, over a 24 hour period (Figure 5.1). 
These initial experiments were carried out in medium 
without IBMX.
IBMX is needed to effectively inhibit 
phosphodiesterase activities (Wells and Kramer, 1981).
The inclusion of IBMX was found to cause an increase 
in the concentrations of intracellular cAMP and 
extracellular cGMP, in response to agonist (Table 5.i). 
Therefore, all subsequent second messenger experiments were 
carried out in medium containing IBMX at 0.5mM (Section
5.2) .
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Figure 5.1: cGMP release in response 
to 1jiM ANP
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Table 5.1.
Comparison of second messenger concentrations in the 
absence and presence of IBMX.
Medium (-IBMX) Medium (+ IBMX) 
0. 5mM
a O.lmM forskolin [cAMP^ (pMol/ml)
5 mins 37.0+9.0 38.9+0.9
1 hour 2 5.2+2.0 42.7+3.0
6 hours 70.0+5.0 8 5.8±7.5
b 1/iM ANP [cGMP]e (pMol/ml)
5 mins 4.0±0.8 5.2+0.7
1 hour 4.8+2.0 12.6+0.3
6 hours 5.4+1.5 11.6+1.2
Results are expressed as Mean + S.E.M. 
a is representative experiment (n=3) 
b is representative experiment (n=4).
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5.3.2. Second-messenger responses during ANP-isoprenaline
interaction
Treatment of cells with 1/liM isoprenaline caused a 
rapid (within 1 min) increase in intracellular cAMP levels 
(P < 0.01), which peaked at 5 mins (P < 0.01) (Figure
5.2). Thereafter, the levels declined, but were still 
significantly higher than control levels, at 6 hours (P < 
0.01) .
ANP (1/xM) did not significantly alter basal 
intracellular cAMP concentration, at any time. However, 
1/iM ANP did attenuate the isoprenaline-induced cAMP 
response (Figure 5.2.). This was found to be significant 
at 5 mins (P < 0.01) and 1 hour (P < 0.01).
Extracellular cGMP concentration was significantly 
stimulated by 1/iM ANP, at 1 hour and 6 hours (P < 0.01) 
(Figure 5.3.). This result was very similar to that 
obtained in the initial experiments (Figure 5.1.). 
Isoprenaline (1/xM) significantly reduced the ANP-stimulated 
cGMP response at 1 hour (P < 0.01) and 6 hours (P < 0.01). 
Throughout the course of the experiment, isoprenaline (1/xM) 
alone caused no change in extracellular cGMP concentration.
In these experiments, it was observed that renin 
release was significantly stimulated as early as 1 hour 
after treatment with isoprenaline (P < 0.05) (Figure 5.4.). 
Furthermore, ANP (1/xM) significantly reduces ^-stimulated 
renin release at 1 hour (P < 0.05). At 6 hours, active 
renin release was stimulated by 1/xM isoprenaline (P <
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Figure 5.2: Intracellular cAMP response during
ANP-isopenaline interaction
pMol cAMP/ml
25-,
20-
1 5 -
10 -
r—- 5  1jjM Iso p ren  
i p  + anp
□  1juM ANP 
C o n tro l
I
6 hr
5 -
NSD
NSD
NSD
1 hr5min1 rain
Time
Each p o in t  i s  Mean + S.E.M.
* *  p<0.01 *  p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
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Figure 5.3: Extracellular cGMP response during
ANP-isoprenaline interaction
pMol cGMP/ml
8 -
ANP5 -
3 -
2 -
Ip  + ANP 
1juM Ip  
C o n tro l
NSD
5min1 min 1 hr 6 hr
Time
Each p o in t  i s  Mean + S.E.M.
* *  p<0.01 # p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
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Figure 5.4: Active renin concentrations during
ANP-isoprenaline interaction
A c t iv e  r e n in  
(p g A j /3  h rs )
100-1
IjjM Iso p ren .
Ip + ANP 
Control60 -
40 -
20 A
6 hr5 min 1 hr1 min
Time
Each p o in t  i s  Mean + S.E.M.
* *  p<0.01 * p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
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0.01). This was antagonised by 1/xM ANP (P < 0.01). Also, 
1/xM ANP caused inhibition of active renin release, at 6 
hours (P < 0.05) (Figure 5.4.).
These results confirm and extend those previously 
presented in Sections 3.3.1, 4.3.1, 4.3.2(ii-iv).
Furthermore, the present study has shown that ANP interacts 
with ^-stimulated renin release as early as 1 hour after 
treatment.
5.3.3. Second-messenger responses during ANP-forskolin 
interaction
Treatment of the cells with O.lmM forskolin (Figure
5.5.) also caused an increase in intracellular cAMP 
concentration, but in quite a different manner to that 
observed in response to isoprenaline. The increase in 
intracellular cAMP is gradual and continuous up until 6 
hours. The increase, in response to O.lmM forskolin is 
significant at 1 min, 5 mins, 1 hour and 6 hours after 
treatment.
Treatment of the cells with 1/iM ANP and O.lmM 
forskolin caused a very similar, gradual increase in 
intracellular cAMP concentration (Figure 5.5.). However 
the inclusion of 1/xM ANP with forskolin (O.lmM) 
significantly potentiated the forskolin-evoked
increase in intracellular cAMP concentration at 1 hour (P < 
0.01) and 6 hours (P < 0.05) (Figure 5.5.).
After treatment with O.lmM forskolin, at 1 min, 1 hour 
and 6 hours, active renin release is significantly
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Figure 5.5: Intracellular cAMP response during
ANP-forskolin interaction
pMol cAMP/ml
130 -i
O.lmM Forsk. 
+ 1/jM ANP
100 -
Forsk.
5 0 -
NSD a  ty-lM ANP 
—  □ControlNSD
1 min 5min 1 hr 6 hr
Time
Each p o in t  i s  Mean + S.E.M.
* *  P<0.01 * p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
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stimulated (P < 0.05) (Figure 5.6.). Forskolin-stimulated 
renin release is significantly reduced by the inclusion of 
1/xM ANP at 1 hour (P < 0.05) and also at 6 hours (P < 0.01) 
(Figure 5.6.).
Extracellular cGMP levels (Figure 5.7.) are stimulated 
by 1/iM ANP, but not by O.lmM forskolin. Both forskolin and 
isoprenaline cause attenuation of the cGMP response to ANP 
(Figures 5.3, 5.7.). Isoprenaline is very efficient
whereas forskolin is less efficient and is ineffective at 6 
hours (c.f. isoprenaline).
5.4. Conclusions
5.4.1. ANP-isoorenaline
Isoprenaline (1/iM) causes a rapid increase in 
intracellular [cAMP], which peaks early (at 5 mins) and is 
followed at 1 hour, by stimulation of active renin release. 
At 24 hours, the effect of isoprenaline (1/iM) on cell 
growth is first evident.
The cAMP response to isoprenaline is reduced by the 
inclusion of 1/iM ANP. Therefore ANP probably attenuates 
isoprenaline-stimulated renin release (and possibly cell 
growth) by reducing intracellular cAMP concentration.
ANP (1/iM) does not alter basal cAMP concentration. 
The observed stimulation of extracellular cGMP in response 
to 1/iM ANP coincided with inhibition of active renin 
release at 6 hours and seems likely to be the mechanism 
whereby ANP inhibits basal renin release.
5.4.2. ANP-forskolin
Forskolin (O.lmM) also causes a rapid increase in
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Figure 5.6: Active renin concentrations during
ANP-forskolin interaction
A c t iv e  r e n in
p g A j/3  h rs  
120-1 Forsk.
100-
C o n t ro l80-
F o r s k .+
NSD
20-
1 hr 6 hr0 1 min 5 min
Time
Each p o in t  i s  Mean + S.E.M.
* *  p<0.01 *  p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
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Figure 5.7: Extracellular cGMP response during
ANP-forskolin interaction
pMol cGMP/ml
13—i
12 —
1 1 -
NSD
**10 -
9 -
8 -
7 -
6 -
5 -
NSD
NSD
2 -
1 min 5min 1 hr 6 hr
Time
Each p o in t  i s  Mean + S.E.WI.
* *  p<0.01 # p<0.05
NSD -  no s i g n i f i c a n t  d i f f e r e n c e
1/jM ANP
Forsk.+ ANP
O.lmM Forsk. 
C o n tro l
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intracellular [cAMP] but this response is sustained and is 
paralleled by stimulation of active renin release.
ANP (1/xM) does not reduce forskol in-stimulated [cAMP]^ 
(rather ANP potentiates it). It was, however, noticeable 
that forskolin was not as effective at lowering ANP- 
stimulated cGMP release, as isoprenaline was. Therefore, 
ANP may, through guanylate cyclase linked receptors, cause 
inhibition of forskolin-stimulated renin release in this 
model.
5.5. Summary
(i) Isoprenaline and forskolin stimulate adenylate cyclase.
(ii) ANP stimulates guanylate cyclase (probably 
particulate).
(iii) ANP inhibits isoprenaline-stimulated renin release 
(and cell growth) and causes a reduction in [cAMP]^.
(iv) ANP inhibits forskolin-stimulated renin release and 
forskolin is not as efficient as isoprenaline is at 
lowering [cGMP]e.
From this summary we can therefore deduce?
(v) ANP has receptors which couid^ e linked, in a negative 
fashion with adenylate cyclase (Section 4.3.1) and in a 
positive fashion with guanylate cyclase.
(vi) Increased [cAMP]^ and reduced [cGMP]e could important in 
stimulation of cell growth in this model system, in vitro.
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CHAPTER 6
The effect of Ajj and converting-enzyme inhibition on renin 
release and cell growth.
6.1. Introduction
The vasoactive effector peptide, angiotensin II (Ajj) 
is known to inhibit renin release from the kidney (Keeton 
and Campbell, 1981). This effect on renin release can be 
considered as a physiological negative feedback loop 
(Figure 1.4.) in the regulation of blood pressure (Davis 
and Freeman, 1976).
It has also been shown that Ajj is active in 
inhibiting renin release from kidney slices and 
nonfiltering kidneys (Shade et al., 1973). The inhibitory 
effect of Ajj on renin release has been shown to be 
dependent on extracellular calcium (Vandongen, 1975; Park 
et al., 1981) and functioning calcium channels (Park et
al.. 1981).
It has been postulated that Ca2+ influx is involved in 
the inhibitory response to Ajj (Kurtz et al., 1984). In a 
later study Kurtz et al. (1986) used the fluorescent Ca2+ 
dye, quin-2, to measure changes in [Ca2+]^ and showed a 
prompt rise in cytosolic Ca2+ in response to Aj j , in 
cultured rat JG cells.
However, a characteristic feature of calcium- 
mobilizing receptors is that they initiate a signal cascade 
leading to the formation of a number of putative second 
messengers (Berridge, 1981, 1982? Irvine et al., 1982?
Takai et al., 1982). The initial event in this cascade is
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specific hydrolysis of membrane phosphoinositides. Ajj has 
been shown to stimulate phosphoinositide metabolism in 
cultured vascular smooth muscle cells (Alexander et al., 
1985? Brock et al. , 1985? Griendling et al., 1986).
Agonists (such as Aj j ) act by stimulating the 
hydrolysis of PtdIns4,5P2 (Figure 6.1) to form 
diacylglycerol and Insl,4,5P3. These two products then 
function as second messengers to activate the two 
independent, but parallel signal pathways.
Diacylglycerol (Figure 6.1) functions within the plane 
of the membrane to increase protein phosphorylation by 
activating C-kinase (Kaibuchi et al., 1982? Takai et al., 
1982? Nishizuka, 1983). Inositol trisphosphate is released 
to the cytosol and is thought to function as a second 
messenger to mobilize calcium from intracellular stores 
(Streb et al., 1983? Joseph et al., 1984). These two
signal pathways appear to function in a synergistic manner 
to stimulate a wide variety of cellular processes.
It is as yet not known, however, whether Ajj exerts 
similar effects on phosphoinositide metabolism in human JG 
cells.
Relatively few studies of the direct effects of Ajj on 
isolated and/or cultured human JG cells have been carried 
out. Pinet et al. (1987) have studied the effects of Ajj 
on prorenin secretion from cultured transfected JG cells, 
but they did not investigate the regulation of active renin 
release.
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Calcium 
stora
It was decided to investigate whether addition of 
exogenous Ajj had any effect on active and prorenin release 
from cultured nephroblastoma cells, and whether Ajj had any 
effect on cell growth. We were also interested in 
determining whether the cells synthesized and released Ajj 
or whether Ajj was formed extracellularly.
Subsequently, it was decided to determine if the 
increase in renin induced by the converting-enzyme 
inhibitor Enalapril(at) in vivo, is mediated through 
interruption of Ajj feedback, using the nephroblastoma 
cells as an in vitro system.
6.2. The effect of Ajj on renin release and cell growth
6.2.1. Short-term experiments
Cells were seeded and grown to confluence (Section
2.3.3.(i)). At the end of the basal incubation period, the 
medium was removed and replaced with medium containing 1/iM 
Ajj and the cells were incubated for 5 hours. The 
concentration of active renin released at 5 hours was 
measured as detailed in Section 2.3.3.(i).
6.2.2. Long-term release and growth rate experiments
In long-term release and growth rate experiments, 
cells were seeded at 2 x 105 cells/ml and grown for 3-4 
days (Section 2.3.3.(iii)). Medium was removed and 
replaced with medium containing Ajj (1/iM) or Enalaprilat 
(1/iM) and growth was continued for up to 12 days. On day 3 
of the experiments, the culture medium was changed and at 3 
day intervals (except in the AII effect on total renin 
release in which the first sample was at 2 days) samples
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were taken for active and total renin estimations (Sections 
2 • 4 • 1 • , 2.4.2.).
Also, in order to determine whether these agents had 
any effect on cell growth, cells were harvested and counted 
at 6 day intervals, as described previously (Section
2.3.3.).
6.2.3. Long-term dose-resoonse experiment to Enalaorilat.
In this experiment, the cells were seeded at 2 x 105
cells/ml and grown for 3-4 days. The medium was removed 
and replaced with medium containing Enalaprilat in the 
range 1/iM to 0. ImM and growth was continued until day 9. 
On day 3 of the experiment, the culture medium was changed 
and on day 3 and day 9 samples were taken for active renin 
estimations and Ajj concentration measurement (Sections
2.4.1. and 2.4.3. respectively).
6.3. Results and discussion
6.3.1. Short-term experiments
Addition of exogenous AII (1/iM) was found to inhibit 
active renin release from cultured human nephroblastoma 
cells, over a period of 5 hours (P < 0.01) (Figure 6.2).
When measurements of Ajj concentration were made 
(Section 2.4.3.), it was found that Ajj levels were high in 
the cell culture medium, to which no Ajj had been added 
(Table 6.1.). This Ajj was found to be formed by renin 
(secreted by the cells) acting on substrate present in the 
foetal calf serum (Table 6.1.).
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Figure 6.2.: Short-term (5h) exposure to 1/iM Aj j .
Active renin release 
(% change)
300-
p<0.01
Agent
s:
• C— . o
<=c o
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Table 6.1.: Ajj concentrations in the cell culture medium.
[Ajjlpg/ml 
Basal 4h
Medium 125.0+6.1 117.4+2.5
+ F.C.S.
Medium Undetectable Undetectable
- F.C.S.
8h
113.8+14.0
Undetectable
Results are presented as Mean + S.E.M. (results of a 
representative experiment).
6.3.2. Long-term release and growth rate experiments. 
Long-term treatment of cells with 1/xM AII inhibited
active (P < 0.01 at day 3) (Figure 6.3.a.(i)) and total (P
<0.01 at day 6) (Figure 6.3.a.(ii)) renin release but had
no effect on cell growth over the 12 day study period.
Long-term treatment with Enalaprilat (1/*M) for 12 days 
caused significant stimulation of active renin release (P < 
0.025) at day 9 (Figure 6.4.a.(i)), but does not cause a
sustained increase of prorenin release (P < 0.025 at day 6
only) (Figure 6.4.a.(ii)). 1/xM Enalaprilat was observed to 
have no effect on cell growth, over a 12 day period, in 
this in vitro system.
6.3.3. Long-term dose response experiment to Enalaprilat. 
The results from the long-term dose response
experiments to Enalaprilat are presented in Figures
6.5.a,b. Enalaprilat was found to suppress extracellular 
Ajj concentrations, in a dose-dependent manner, with a 
concomitant stimulation of active renin release (Figures
6.4.a,b).
6.4. General discussion
In this study it was found that Ajj acts directly on 
renin-secreting cells to reduce secretion of both active 
renin and prorenin. Furthermore, Ajj measurements showed 
that extracellular endogenous Ajj levels in contact with 
the cells were high. Therefore, it is likely that these 
cells are basally suppressed by high endogenous Ajj levels.
In order to test this, cells were incubated in 
the presence of converting-enzyme inhibitor. Long-term
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Figure 6.3. s Long-term action of Ajj (1/iH) on (a) (i)
active renin release and (b) cell growth.
Active renin (jjU/ml)
6 O-1
Control
(i)
20-
p<0.001
p<0.01 + +  P‘0.001
10 122
Cel 1 no. x 10^/ml
Control 
£  All (IjjM) 
NSD(b) NSD
10-
6 12
Days
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Figure 6.3. (a) (ii): Long-term action of Ajj (1/iM) on total
renin release.
Total renin (till/ml)
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P<0.001
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✓
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600-
200 -
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Figure 6.4. s Long-term action of Enalaprilat *(l/xM) on
(a)(i) active renin release and (b) cell 
growth.
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Figure 6.4.(a)(ii): Long-term action of Enalaprilat
(1/iM) on total renin release.
Total renin (jjU/ml)
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treatment of the cells with 1/xM Enalaprilat caused 
stimulation of active, but not prorenin release. 
Enalaprilat was found to be effective at lowering 
endogenous Ajj levels and this is probably the mechanism 
whereby it increases active renin release (i.e. 
intervention of Ajj negative feedback).
However, Enalaprilat (1/xM) is less effective at 
stimulating prorenin release and this may be because Ajj is 
Xess effective at reducing prorenin compared with active 
renin in this system.
Aj j, which has been reported to promote the growth of 
vascular smooth muscle cells in culture (Lyall et al., 
1988a) had no effect on the growth of cultured 
nephroblastoma cells throughout the 12-day study period.
Geary et al. (1990) have shown (using the reverse 
hemolytic plaque assay) an increase in renin secretion by 
recruitment of renin-secreting cells in rats treated with 
Enalapril. In contrast, this study showed that Enalaprilat 
had no significant effect on cell growth.
Also, Geary et al. (1990) found that Enalapril did not 
affect the amount of renin secreted by each cell. In 
contrast, this study showed that Enalaprilat causes 
increased release of active renin per cell.
The feedback suppression by Ajj acts by inhibiting 
active renin and prorenin release per cell. Johns et al. 
(1987) have reported that Ajj suppresses renin gene 
expression in rat kidney.
Whether or not the observed inhibition of renin
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release (in response to Aj j) from cultured nephroblastoma 
cells reflects suppressed renin synthesis and gene 
expression is, as yet, unknown. Further studies would be 
necessary to resolve this point.
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CHAPTER 7
G-protein expression in membranes prepared from human 
cultured nephroblastoma cells.
7.1. Introduction
Guanine nucleotide-binding proteins (G-proteins) are a 
family of closely related membrane proteins that are 
involved in the transduction of signals from cell surface 
receptors to their effectors. Receptors for many hormones, 
growth factors and neurotransmitters, which control the 
rate of production of second messengers, such as Ins 
1,4,5P3 and cAMP, are dependent upon the intermediate 
activation of one, or more G-protein(s).
Members of this family include both rod and cone 
transducins, Gs and G^, which respectively couple receptors 
(Figure 7.1) to the stimulation or inhibition of adenylate 
cyclase (Birnbaumer et al., 1985; Gilman, 1987; Spiegel,
1987) and also GQ. GQ is highly concentrated in the brain 
(Rouot et al., 1987), where it accounts for approximately 
1% of the total cortical membrane protein, and other neural 
tissue. GQ is thought to be involved in the functional 
coupling of opiate receptors to neuronal voltage-dependent 
calcium channels (Hescheler et al., 1987).
7.1.1. G-protein structure
G-proteins consist of three non-identical subunits 
termed a, 0 and $ . The unique a-subunit appears to
function to regulate its specific effector system, with the 
exceptions of receptor-regulation of phospholipase A2 
activity (Jelesma and Axelrod, 1987), and perhaps some
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Figure 7.1: Basic constituents of a hormone-sensitive 
adenylate cyclase system.
Glucagon  
V a s o p re s s in  (VPj)  
LH. FSH, TSH  
A C T H  
E p i n e p h r i n e (/3's)
Opioids 
SRIF 
Angiotensin II 
ACh (M)  
Epinephrine ( 0<2 )
OCioc
Catalytic subunit of 
adenylate cyclase.
▼
CAMP
Receptors which, when occupied, cause increases in 
cAMP levels are termed Rs and those which bring about 
decreases in cAMP are termed . At the centre of the 
coupling process between the receptors and the altered 
adenylate cyclase activity are two signal-transducing 
proteins which bind Mg2+ and guanine nucleotides. One, Gs, 
mediates the effects of R^, the other, , mediates the 
effects of R^ receptor binding (from Birnbaumer et al., 
1985).
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degree of the control of inhibition of adenylate cyclase. 
The a-subunits vary in size from 39 to 52 kDa however at 
the level of primary amino acid sequence they are very 
highly conserved. They also bind guanine nucleotides with 
high affinity and contain an intrinsic GTP'ase activity 
which is essential for their normal function (for reviews 
see Casey and Gilman, 1988; Milligan, 1988).
Heterogeneity of Gs a subunits was first noted during 
the purification of Gs (Northup et aJ. , 1983). Most
tissues contain a mixture of two major forms of Gs a. 
Individual forms of Gs a can be generated by differential 
splicing of the pre mRNA transcribed from the gene for Gs a 
(Bray et al., 1986). In all of the individual forms,
however, the C-terminal decapeptide is conserved.
Two forms of the /9-subunit with molecular masses 35kDa 
and 36kDa have been identified immunologically (Roof et 
al. . 1985) and, more recently, the identification of cDNA 
clones for two separate forms of the /3-subunit has 
confirmed the presence of at least two genes encoding /3- 
subunits (Gao et al., 1987).
The if -subunits are polypeptides of between 8 and 
lOkDa. Immunological evidence suggests the expression of a 
number of forms, however, relatively little work has been 
performed on their identification and function. In all 
physiological situations, the /3-subunit remains tightly 
associated with its relevant if -subunit.
7.1.2. G-protein function
The function of the G-proteins is to couple agonist-
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activated receptors to the effector systems that alter 
intracellular concentrations of second messengers. As this 
process must be of limited duration, the G-protein is 
required to undergo a cyclical pattern of activation 
followed by a subsequent deactivation (Figure 7.2).
In the resting state the G-protein exists in a complex 
consisting of a, 0 and if subunits, with GDP bound to the 
nucleotide binding site of the a-subunit. Upon receptor 
activation of the G-protein (Figure 7.2), the rate of 
release of GDP (which appears to be the rate-limiting step 
in the G-protein activation/deactivation) is enhanced and 
the released GDP is replaced by GTP (reviewed by Gilman, 
1987) .
With GTP in the nucleotide binding site and in the 
presence of Mg2+, then the holomeric G-protein can 
dissociate into an active a-subunit with GTP bound and free 
/?/ if subunits. This active a-subunit is then able to 
interact with the catalytic moiety of a particular second- 
messenger-generation system to alter the rate of synthesis 
of the second messenger.
Hydrolysis of the terminal phosphate of the bound GTP 
by the intrinsic GTP'ase activity deactivates the a subunit 
and in this GDP-bound form, it is then able to reassociate 
with 0/ if subunits to restore the G-protein to the 
deactivated state.
7.1.3. G-protein identification
The traditional means of identifying Gs and G^ has
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Figure 7 2: The role of GTP binding and hydrolysis in the 
activation and deactivation of a typical G- 
protein.
Receptor + agonist
GDP -
messenger 
I;! system ij|i|
I
Activated receptor-agonist 
complex
i fil: 2nd i||;i|li
2nd
messenger 2nd messenger 
jjfef' system |||l||
Source: Milligan, 1988
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relied on the ability of cholera toxin to catalyse the 
transfer of [32P]ADP-ribose from 32P-NAD+ to Gs a (Figure 
7.1) and of pertussis toxin to catalyse an analogous ADP- 
ribosylation of a (Katada and Ui, 1982? Milligan et al.. 
1985).
ADP-ribosylation of the a subunit of Gs inhibits its 
GTP*ase activity thereby permanently stimulating adenylate 
cyclase. Pertussis toxin ADP-ribosylates the a subunit of 
G^ and this blocks its effect on adenylate cyclase and 
thereby removes the inhibitory action of G^.
However, limitations of these procedures have included 
either, for cholera toxin, the requirement for a 
proteinaceous cofactor (ARF) (Kahn et al., 1988) or, for
pertussis toxin, the identification of a considerable 
number of substrates for the toxin (Milligan and Klee, 
1985). These include GQ (Goldsmith et al., 1988) as well
as G-proteins named G^l, G^2 and G^3 (Jones and Reed, 
1987).
This has led to the generation of both polyclonal and 
anti-peptide antisera able to identify specifically a 
number of different G-proteins (Backlund et al., 1988;
McKenzie et ai. , 1988). Information taken from cDNA
clones, corresponding to the various G-proteins allowed the 
generation of anti-peptide antisera against sequences which 
are unique to the various gene products (Backlund et al. . 
1988? Mullaney et al., 1988).
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7.2. Basis for assessment of G-protein expression in
nephroblastoma cell membranes 
In this study it has previously been shown (in 
Chapters 3, 4 and 5) that renin release from cultured
nephroblastoma cells is stimulated by the /3-adrenergic 
agonist, isprenaline. This was found to involve an 
increase in intracellular cAMP concentration and is thought 
to involve adenylate cyclase activation. In the present 
study, it has also been shown that ANP inhibited renin 
release and, furthermore this inhibition was removed by the 
presence of pertussis toxin. This would therefore imply 
the involvement of a pertussis toxin-sensitive G-protein in 
ANP inhibition of renin release in this model, in vitro.
In this study, highly selective anti-(G-protein) 
anti-peptide antisera have been used to assess the 
expression of G-proteins in membranes prepared from human 
cultured nephroblastoma cells.
7.3. Immunological analysis
Membrane preparations from the cultured nephroblastoma 
cells were carried out, as described in Section 2.5.1. 
Membrane protein concentration was determined using the 
method of Lowry et al.(1951) (Section 2.2.5.). Membrane 
samples were resolved by SDS/PAGE and immunoblotted, as 
detailed in Section 2.5.2.
The generation and specificities of the various 
antisera used in this study are defined in Table 7.1.
Antiserum SG2 is an anti-peptide antiserum produced
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Table 7.1s Generation and specificities of antisera used.
Anti-
serum:
Peptide
employed:
Corresponding
G-protein
sequence:
Antiserum
identifies:
SG2 KENLKDCGLF TD1(341-350) TD1, TD2,
Gil, G±2
I1C LDRIAQPNYI G^l(159-168) Gil
CS1 RMHLRQYELL Gs (385-394) G S
0N2 GCTLSAEERAALERSK Gq (1-16) Go
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against the C-terminal decapeptide of rod transducin. This 
antiserum identifies forms of as well as transducin. 
However, as transducin is limited in distribution to 
photoreceptor-containing tissues, this antiserum (SG2) can 
be used as a probe for forms of G^ in other tissues 
(Backlund et al., 1988? McKenzie et al., 1988).
Antiserum I1C (Table 7.1) was raised against a peptide 
corresponding to amino-acids 159-168 of a^l (Green et al., 
1990).
Antiserum CS1 was raised against a peptide (Table 7.1) 
corresponding to the C-terminal decapeptide of Gs a 
(Milligan and Unson, 1989).
Antiserum ON2 was raised against a synthetic peptide 
corresponding to a specific region of the a-subunit (1-16) 
of GQ (Mullaney and Milligan, 1990).
For molecular-mass estimations on immunoblots, 
prestained molecular-mass markers were subjected to 
SDS/PAGE in parallel with the test samples.
Immunoblotting with the above antisera was then 
performed as described in Section 2.5.2.
7.4. Results and discussion
The results obtained using the above antisera are 
summarized in Table 7.2.
7.4.1. Assessment of G  ^expression
Antiserum SG2 identifies G^l and G^2 equally, as these 
two proteins have an identical sequence in the region used 
to generate the antiserum. This antiserum does not 
identify G^3.
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Table 7.2: 6-protein identification in nephroblastoma 
cell membranes.
Antiserum
employed:
Antiserum
identifies:
Presence or 
absence of 
G-protein:
SG2 TD1, TD2, present
Gil, G±2
I1C Gil absent
CS1 Gs present
ON 2 Go absent
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Antiserum SG2 identified a single polypeptide in human 
nephroblastoma cell membranes of 39-40kDa (Figure 7.3.).
In order to determine whether this polypeptide 
corresponded to G^l or G^2, an antipeptide antiserum which 
is able to discriminate between G^l and G^2 was employed. 
Antiserum I1C identifies only Gj_l. No immunoreactivity to 
this antiserum was observed in human nephroblastoma cell 
membranes (results not shown), thus demonstrating that the 
39-40kDa polypeptide was indeed G^2.
7.4.2. Assessment of Gz expression
The presence of Gs a was identified using the 
antiserum CS1. Two major forms of Gs a (Section 7.1.1.) 
are present, of molecular mass 40kDa and 42kDa (Figure 
7.4), in membranes from cultured nephroblastoma cells.
7.4.3. Assessment of GQ expression
Antiserum 0N2 recognises GQa. However, no
immunoreactivity to antiserum 0N2 was observed in membranes 
from cultured nephroblastoma cells (results not shown).
Interestingly, GQ has previously been reported to be 
expressed in small amounts, in bovine kidney medulla (Huff 
et al., 1985) and also in a variety of cultured cell lines 
(e.g. Mullaney et al., 1988).
7.5. Conclusions
In conclusion, the present study has shown that Gs and 
G^2 are expressed in membranes of human cultured 
nephroblastoma cells.
140
43kDa
Figure 7.3: Identification of G^2 in human nephroblastoma 
cell membranes.
Membranes from (A) rat cerebral cortex (100/xg) , (B) , (C)
vascular smooth muscle cells (330, 280nq), (D) human
nephroblastoma cells (12 0^g) were resolved and 
immunoblotted, as described in Section 2.5.2. The blot was 
developed using antiserum SG2 (1:200 dilution) as the 
primary reagent.
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A B  C D E F G  H
Figure 7.4: Identification of Gs in human nephroblastoma
cell membranes.
Membranes from (A) human nephroblastoma cells (120/xg), (B)-
(H): rat; brain (B), liver (C), heart (D), adipocytes (E), 
renal cortex (F), renal cortex (partially purified) (G) and 
vascular smooth muscle cells (H) (all lOO^g), were resolved 
and immunoblotted, as described in Section 2.5.2. The blot 
was developed using antiserum CS1 (1:200 dilution) as the 
primary reagent.
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These results are reassuring, because, in this study, it 
has been demonstrated that 0-stimulated renin release (and 
cell growth) by isoprenaline involves increased [cAMP]^ 
probably mediated by adenylate cyclase stimulation. Also, 
this study has already demonstrated (in Section 4.3.1) 
that ANP-inhibited renin release was blocked by the 
presence of pertussis toxin, which suggested the 
involvement of a pertussis toxin-sensitive G-protein, which 
probably mediated inhibition of adenylate cyclase.
However, the detection of both Gs and G^2 in the 
nephroblastoma cell membranes is not surprising since both 
Gs and G^2 are ubiquitous? being found in essentially all 
cells of vertebrates (Spiegel, 1987).
Nevertheless, to date, as far as we are aware, no-one 
has reported the expression of Gs and G^2 in human cultured 
nephroblastoma cell membranes.
In addition however, further studies will be necessary 
in order to determine whether Gs and G^2 are functional in 
the stimulation and inhibition of adenylate cyclase 
activity, respectively.
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CHAPTER 8
Immunocytochemistry and electron microscopy studies of 
human cultured nephroblastoma cells.
8.1. Introduction
8.1.1. JG granular cells
It is now certain that the juxtaglomerular (JG) 
granular cell is the site of intrarenal synthesis of renin, 
as judged by immunohistochemistry (Taugner et al., 1979;
Faraggiana et al., 1982; Lindop and Downie, 1984a; Lacasse 
et al., 1985).
The fine structure of normal, human JG cells has been 
studied in detail, both at the light and electron 
microscopic levels by Biava and West (1966), who confirmed 
the view that the JG cells represent modified arteriolar 
smooth muscle cells. The persistence of cytoplasmic 
myofibrils, the general organization of the endoplasmic 
reticulum and the structural appearances of mitochondria 
closely relate the JG cells to arteriolar smooth muscle 
cells.
However, one feature which is specific to the JG cell 
is the appearance of renin storage granules. Rhomboid 
protogranules, containing a crystalline (immature) form of 
renin were observed by Lacasse et al. (1985) in the JG 
cells of newborn mice.
The coalescence and eventual fusion of these 
protogranules, results in the formation of mature renin 
granules (Pratt et al., 1983; Galen et al., 1984; Lacasse 
et al., 1985).
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The concentration of renin has been reported to 
increase from rough endoplasmic reticulum to Golgi complex 
to secretory granules (Lacasse et al., 1985), and about 60% 
of the cellular renin activity is thought to be localized 
in the mature granules (Morimoto et al., 1979).
The mature granules are located mostly in the 
periphery of the cell (Taugner et al., 1984). Smaller
renin granules, of varying homogeneity, may be found 
clustering around the Golgi complex (Barajas, 1966).
8.1.2. Nephroblastoma cells
The renin secreting cells in the kidney are thought to 
be derived from undifferentiated mesodermal cells adjacent 
to the blood vessels in the metanephric renal cortex (Phat 
et al., 1981).
Nephroblastoma or Wilms' tumour is a tumour of 
pluripotent mesodermal cells which can differentiate not 
only into all structures of the normal kidney, but also 
other mesodermal tissues, such as bone and skeletal muscle.
It is therefore, not surprising that nephroblastoma 
cells can differentiate into renin secreting cells and that 
these renin secreting cells would be associated with the 
blood vessels (Lindop et al., 1987), mimicking the known
developmental pattern of JG cells (Phat et al., 1981).
There have been previous descriptions of renin 
secreting nephroblastomas (Mitchell et & 1., 1970? Day and 
Luetscher, 1974; Carachi et al., 1987a). The evidence is 
based on high concentrations of prorenin in the pre-
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operative plasma and normal plasma prorenin concentrations 
after removal of the tumour.
Inglis and Leckie (1990) have shown that prorenin (and 
active renin) were secreted from the tumour cells, by 
growing the nephroblastoma cells in vitro and monitoring 
the secretion of renin into the growth medium.
8.1.3. Characterization of cultured nephroblastoma cells
8.1.3.(i) Immunocvtochemistrv
In order to further characterize the cells, an 
immunocytochemical study was carried out, using standard 
techniques (Section 2.6). This involved staining the cells 
with antisera to vimentin (which is the main protein 
subunit of intermediate filaments of cells of mesenchymal 
origin) and to a battery of epithelial cell markers, such 
as cytokeratins and epithelial membrane antigen (EMA).
In order to determine if the cells contained 
intracellular (stored) renin, immunostaining was carried 
out , using two separate renin antisera? one was raised in 
rabbits using human renin purified from a JG cell tumour. 
The purity of the renin and the specificity of this 
antisera have been documented (Galen et al., 1979).
The other antiserum was raised in rabbits against pure 
human renin from cadaver kidney cortex (McIntyre et al., 
1983) . The specificity of this antiserum has also been 
determined (Lindop et al., 1987? Inglis and Leckie, 1990).
These antisera were used in the peroxidase-anti- 
peroxidase (PAP) technique, which has been described in 
detail elsewhere (Lindop et al.. , 1983,a,b? Lindop and
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Downie, 1984a; Lindop et al., 1984b, 1987).
8.1.3.(ii^  E.M. studies
It was decided that a study of the ultrastructure of 
the cultured nephroblastoma cells should be carried out; in 
particular, to determine whether or not the cells contained 
storage granules.
Therefore, E.M. studies of human cultured 
nephroblastoma cells (at the 7th subculture) were carried 
out using standard techniques (Section 2.7.).
8.2. Results and discussion
8.2.1. Immunocvtochemistrv
There was negligible intracellular staining of renin, 
using the two antisera described previously (Section
8.1.3.(i)).
It is likely that renin is secreted from the 
nephroblastoma cells soon after synthesis.
The nephroblastoma cells were also stained with 
antisera to vimentin and to a battery of epithelial cell 
markers.
The cells were only positive for vimentin, which is 
consistent with mesenchymal differentiation (results not 
shown).
8.2.2. E.M. studies
E.M. studies of human cultured nephroblastoma cells 
showed the presence of myofilaments and dense condensations 
(Figure 8.1). Also, the cells were observed to contain 
glycogen granules (Figure 8.2) and an abundant and dilated, 
rough endoplasmic reticulum (Figures 8.1, 8.2) indicative
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Figure 8.1.s Low-power E.M. photograph of human
nephroblastoma cell in culture.
A prominent nucleus (N) with nucleolus (Nuc) is present. 
Note also the presence of myofilaments (M) ; microvilli 
(Mv) ; dilated rough endoplasmic reticulum (RER); liposomes 
(L) and glycogen (G).
(Final magnification: X8000).
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Figure 8.2.: High-power E.M. photograph of intracellular
features of nephroblastoma cell in culture.
This is an enlargement of the area outlined and marked 'lf 
in Figure 8.1. which, at greater magnification, shows, 
myofilaments (M); liposome (L) and glycogen (G).
(Final magnification: X 23000).
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of a cell which is active in protein synthesis.
All of these features were suggestive of myoid 
differentiation. These results are consistent with those 
of Lindop and Gardiner (1986) who described the JG cells as 
myoepitheliod because their morphology is intermediate 
between that of endocrine and smooth muscle cells.
At higher magnifications (Figures 8.2, 8.3) the cells 
were also observed to have poorly differentiated Z-bands 
(Section 8.1.2), which is consistent with nephroblastoma.
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Figure 8.3: High power E *M. photograph of myofilaments
present in nephroblastoma cell in culture.
Note the presence of poorly-differentiated 'Z' bands (Z) . 
(Final magnification: X 23000).
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CHAPTER 9
Karyotype analysis of human cultured nephroblastoma cells.
9.1. Introduction
9.1.1. Nephroblastoma (Wilms1 tumour).
Nephroblastoma or Wilms* tumour, is one of the most 
common paediatric malignancies (Cutler and Young, 1975).
Two distinct forms of Wilms* tumour have been 
described i.e. hereditary (or familial) and non-hereditary 
(or sporadic) and the disease can be either unilateral, 
bilateral or multifocal in terms of the affected kidney(s). 
The hereditary form is the rarer, comprising only 1% of the 
diagnosed cases (Matsunaga, 1981) but is inherited as an 
autosomal dominant trait with variable penetrance 
(Matsunaga, 1981).
Whereas the hereditary form has a greater frequency of 
bilateral disease (i.e. both kidneys affected), the great 
majority of cases are of the sporadic form and affect only 
one kidney (99% of cases, 97% unilateral) (Maitland et al., 
1989).
9.1.2. Identification of a possible Wilms* tumour gene 
Both sporadic and syndrome-associated Wilms * tumours
are accompanied by an increased frequency of abnormalities 
of the urinary tract and genitalia (Breslow and Beckwith, 
1982) .
Deletion analysis of individuals with the WAGR 
syndrome (Davis et al., 1988; Compton et al., 1988) (for, 
Wilms* tumour, aniridia, genitourinary abnormalities and 
mental retardation) showed that a Wilms* tumour gene lies
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at chromosomal position llpl3 (ISCN, 1985) (Figure 9.1).
This led to the isolation of a candidate Wilms* tumour 
gene (Gessler et al., 1990), encoding a zinc-finger protein 
which is likely to be a transcription factor.
Recently, it has been reported by Pritchard-Jones et 
al. (1990) that the candidate Wilms* tumour gene (WT2-1) 
(Call et ai. , 1990) is expressed specifically in the
condensed mesenchyme, renal vesicle and glomerular 
epithelium of the developing kidney, in the related 
mesonephric glomeruli and in cells approximating these 
structures in tumours.
The data obtained by this group suggest that the 
candidate gene, which lies at chromosomal position llpl3 is 
indeed a Wilms* tumour gene which has a specific role in 
kidney development and a wider role in mesenchymal- 
epithelial transitions.
9.1.3. Karyotype analysis of nephroblastoma cells
In order to characterize the nephroblastoma cells more 
fully, the karyotype of the cells was determined, using the 
methods as detailed in Section 2.8.
It was decided to determine whether the cultured cells 
contained any karyotype abnormalities previously reported 
to be associated with the Wilms* tumour phenotype and also 
whether the cells were composed of one or more cell 
population(s).
9.1.4. G-bandinq of nephroblastoma cell chromosome spreads
Subsequently, banding of the chromosomes was carried
out (Section 2.8.2.(ii)). Banding techniques and what they
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Figure 9.1s Diagram of a banded human karyotype.
(ISCN 1985)
154
reveal about chromosome structure have been reviewed in 
many articles (e.g. Dutrillaux, 1977; Ris and Korenberg, 
1979).
This enables abnormalities on individual chromosomes 
to be detected. Of particular interest were chromosomes 11 
and 1 on which the genes for Wilms* tumour (Pritchard-Jones 
et al.. 1990) and control of renin activity (Wilson and
Taylor, 1982), respectively, are reported to be located.
9.2. Results
9.2.1. Karvotvoe analysis
The karyotype of human cultured nephroblastoma cells 
(at the 8th subculture) was examined.
Several cells were analysed, the modal number of 
chromosomes was 46 and the karyotype was determined as 46XX 
(female) (Figure 9.2).
Therefore, the cells did not have any visible 
abnormality associated with a malignant phenotype and were 
clonal.
9.2.2. G-banding
Banding of the chromosomes revealed no abnormal 
chromosomes (Figure 9.3). Both copies of chromosome 1 and 
chromosome 11 appeared normal.
A typical banded karyotype is shown in Figure 9.3.
9.3. Discussion
In the light of recent reports concerning a candidate 
Wilms* tumour gene, it would of course, be very interesting 
to determine whether or not, the nephroblastoma cells in 
culture (which have already been shown to indicate
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mesenchymal differentiation (Section 8.2.1)) express the 
candidate Wilms* tumour gene (WT2-1).
To our knowledge analysis of WT2-1 expression has only 
been carried out in Wilms* tumour tissue sections and not 
in nephroblastoma cells which have been maintained in 
culture.
However, more than one locus has been implicated in 
the disease (Grundy et al., 1988; Huff et al., 1988) and it 
is possible that different loci may be implicated in 
different tumours even though the tumours are 
histologically indistinguishable (Grundy et al., 1988).
However, to conclude, no obvious abnormalities in the 
karyotype or banding of chromosomes in the cultured 
nephroblastoma cells were found.
This does not exclude the possibility that some 
chromosomal abnormalities at the level of the gene may be 
present.
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CHAPTER 10
GENERAL DISCUSSION
10.1. Introduction
The aim of the present study was to investigate the 
control of renin release, using a novel in vitro model 
system: cultured human nephroblastoma cells. Studies of
the intracellular control of renin release are extremely 
difficult to perform in cells derived from normal kidney, 
since JG cells form only a small proportion of the total 
cell population (Fray and Park, 1987).
Renin-secreting tumour cells have been described 
previously. Human tumoral JG cells were maintained in 
culture by Conn et al. (1972), and also by Galen et al., 
(1984). However, in both instances the cells were primary 
cultures secreting mostly prorenin. Pinet et al. (1985) 
carried out SV40 transformation of human tumoral JG cells, 
thereby establishing a continuous culture of human JG 
cells. However, the level of renin released from the 
cells was low and more than 95% of the renin secreted into 
the medium was in an inactive form.
In the nephroblastoma cell model system, active renin 
represents 10% of the total renin released from the cells 
(Table 10.1). The proportions of active : total renin
released by the cells are very similar to those found in 
the nephroblastoma patient's plasma (Carachi et al.. 
1987a).
Although the cells were derived from a tumour, renin
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Table 10.1: Renin concentrations in nephroblastoma cell
cultures.
(grown in Medium 199 + 15% F.C.8.).
Renin (jiU n its /m l) ± S.EM£n=3)
Active Inactive
Cell supernatant : 11.0 ± 0.1 
C ontrol (Medium 199) : 0.0
90.0 ± 0.2 
0.6 ±0 .0
(Values obtained from Day 4 samples, 8th subculture)
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release was controlled by some of the agents that are known 
to regulate secretion from the normal human kidney.
10.2. fl-adreneraic agonists stimulate renin release and 
nephroblastoma cell growth.
The present study has shown that isoprenaline (O.lmM); 
forskolin (O.OlmM) and dbcAMP (O.lmM) stimulate active 
renin release at 5 hours. Treatment of the cells with 1/xM 
isoprenaline for 12 days stimulated active and total renin 
release from the cells.
An unexpected and potentially important finding was 
that when given long-term, isoprenaline (1/iM) stimulated 
nephroblastoma cell growth. The present study has shown 
that 1/iM isoprenaline causes an increase in renin release 
by stimulating cell growth, which is first evident at 24h. 
The action of isoprenaline on both renin secretion and cell 
growth was blocked by propanolol, indicating a specific 
action on the /3-receptor.
The intracellular messenger involved in signal 
transduction from the /S-receptor is cAMP and we found that 
its analogue, dbcAMP also increased renin secretion by 
stimulating cell growth (increased cell growth was also 
first evident at 24h).
Forskolin stimulates the catalytic subunit of 
adenylate cyclase directly, leading to increased 
intracellular concentrations of cAMP (Seamon et al., 1981). 
Forskolin (O.lmM) also caused stimulation of renin release 
and cell growth. However, unlike isoprenaline and dbcAMP,
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forskolin caused an increase in the long-term by 
significantly increasing renin release per cell.
This result is in contrast to recent work reported by 
Everett et al. (1990). This group has reported (using the 
reverse hemolytic plaque assay) that forskolin 
administration resulted in an increase in the number of 
renin-secreting microvascular cells without changes in the 
amount of renin secreted by individual cells.
The differences observed could be due to:
1) Different doses (and number of additions) of forskolin; 
O.OlmM added at lh intervals for 3h (Everett et al., 1990) 
compared with O.lmM added at the start of a 24h experiment 
(the present study).
2) Different in vitro model systems used? freshly isolated 
developing kidney microvessels compared with cultured 
nephroblastoma cells.
Alternatively, it could be possible that forskolin, 
acting via an increase in [cAMP]^, can stimulate two 
pathways to cause either 1) an increase in renin release 
per cell number or 2) an increase in the number of renin- 
secreting cells.
10.3. Possible mechanism(s) involved in fl-adrenerqic- 
stimulated cell growth
The actions of /9-receptor agonists in stimulating cell 
growth were unexpected.
The mechanism of the effect of /9-receptor agonist 
stimulated cell growth is unknown. However, other workers 
e.g. Rozengurt et &1. (1983) have reported that a sustained
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increase in cellular cAMP concentrations acts as a 
mitogenic signal for Swiss 3T3 cells in culture.
The catalytic subunit of cAMP dependent protein kinase 
may be involved in the regulation of the proto-oncogene, c- 
fos (Riabowol et al., 1988). c-fos, in association with 
another proto-oncogene c-jun, binds to the 
tetradecanoylphorbol acetate responsive element which is 
found in the promoter region of several genes, c-fos/c-iun 
are involved in both cell proliferation and cell 
differentiation (Zelenka, 1990) . It is likely that /9- 
receptor agonists are not themselves mitogenic but augment 
the action of mitogens (e.g. PDGF? Rozengurt et al., 1983), 
either in the foetal calf serum or even possibly secreted 
by the cells themselves.
From this work, it seems that /9-agonists have two 
actions: in the short-term they stimulate renin release,
probably through increased rate of exocytosis or renin gene 
expression; longer-term administration of isoprenaline (or 
dbcAMP) also led to an increased number of renin-secreting 
cells and consequently a sustained and long-term increase 
in renin release. This finding could be applicable to 
other mammalian hormones, namely agonists, effective in the 
short-term may have a dual role as growth factors on the 
hormone-secreting target cell, allowing a sustained hormone 
response to increased demand.
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10.4. ANP inhibits basal renin release and B-stimulated
renin release and cell growth
The present study has also shown that renin secretion 
from human cultured nephroblastoma cells is responsive to 
ANP.
ANP (1/xM) caused a marked inhibition of basal renin 
release at 5h and this was paralleled by an increase in 
extracellular cGMP concentration.
Furthermore, this study has shown that ANP attenuated 
isoprenaline (1/iM)- and forskolin (0.ImM)-stimulated renin 
release and (in the case of isoprenaline) /^-stimulated cell 
growth, at 24 hours.
10.5. Second-messenger involvement in the control of renin 
release
Subsequently, an investigation into the second 
messengers involved in the observed responses, was carried 
out. Isoprenaline (1/iM) caused an immediate stimulation of 
[cAMP]^, which peaked early, and this was followed by an 
increase in active renin release at lh. Forskolin (O.lmM) 
caused a sustained increase in [cAMPJ^ which was paralleled 
by an increase in active renin release.
ANP was found to be effective at lowering 
isoprenaline-stimulated intracellular [cAMP] in cultured 
nephroblastoma cells. This has also been observed to occur 
in rat adrenal cortical membrane preparations (Anand- 
Srivastava et al.., 1985); aorta washed particles,
mesenteric artery and renal artery homogenates (Anand-
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Srivastava et al., 1984).
The involvement of cAMP in the control of renin 
release has been suspected but the only direct study 
involving cAMP measurements was by Pinet gt al. (1987) . 
This group found that prorenin and cAMP release were 
stimulated by forskolin. They also found that ANP reduced 
forskolin-stimulated prorenin release but did not affect 
cAMP release.
The results from the present study have shown that ANP 
did not reduce forskolin-stimulated increases in [cAMP]^, 
but was effective at lowering forskolin-stimulated active 
renin release. The present study also showed that ANP 
caused a significant potentiation of forskolin-evoked 
intracellular [cAMP] (c.f. Pinet et al., 1987).
Results of the present study showed that ANP reduced 
isoprenaline-stimulated renin release and [cAMP]^ (Figure 
10.1). The action of ANP on reducing adenylate cyclase 
activity has been shown in several systems (e.g. Anand- 
Srivastava et al., 1984, 1985) but not in conjunction with 
changes in renin release.
The present study showed that ANP stimulated cGMP 
release in this cell line. This observation agrees with 
the literature in that ANP has been shown to act through 
cGMP in other systems (Winguist et al., 1984; Ishikawa et
al., 1985; Kurtz et al., 1986). The present study suggests
coutd,
that cGMPAinhibit basal renin release. It may be the 
mechanism by which forskolin-stimulated renin release is 
suppressed (Figure 10.1).
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Figure 10.1
A highly schematic representation of second messenger 
involvement in the control of renin release from cultured 
nephroblastoma cells, (a) The effects of; 0-agonists and 
ANP when added separately (b) The effects of isoprenaline 
and ANP when added together and (c) The effects of 
forskolin and ANP when added together.
(Solid lines indicate known mechanisms of hormone (or drug) 
action, dotted lines indicate putative mechanisms of 
action; + ve and - _ ve represent stimulatory and 
inhibitory effects, respectively).
(a) isoprenaline 0 ve
© v e  _  A ;C - | t  tc A M p \; t  f  r.r.
Hypothetical nephroblastoma 
cell.
forskolin
ANP
g o ]  f  tc G M P /; | J r.r.
(b)
isoprenaline — jSjve Hypothetical nephroblastoma 
cell
cAMP
r.r.
G.C. cGMP
ANP
(c)
forskolin
cAMP
cGMP
Hypothetical nephroblastoma 
\  cell
ANP
f t  r.r.
Where A.C. and G.C. represent adenylate cyclase and guanylate 
cyclase. 'R' represents receptor; catalytic subunit of adenylate  
cyclase is represented by 'C \ Upward pointing and downward 
pointing arrows represent increases and decreases in cAMP or 
cGMP formation and in renin release (r.r.).
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10.6. Expression of Gz and G^2 in nephroblastoma cell 
membranes
Results from the present study show that 
nephroblastoma cells in culture have adenylate cyclase and 
guanylate cyclase (probably particulate) activity.
They also have ANP receptors, which are linked, in a 
negative fashion to adenylate cyclase and in a positive 
fashion to guanylate cyclase (Figure 10.1).
In the present study, the presence of Gs and G^2 (the 
G-proteins reported to be involved in the stimulation and 
inhibition of adenylate cyclase, respectively) has also 
been demonstrated, using pertussis toxin and immunoblotting 
techniques. However, further studies would be necessary in 
order to determine whether the G-proteins detected were 
functional or not.
10.7. Ajj exerts feedback inhibition on renin release from
cultured nephroblastoma cells, which can be released bv 
Enalanrilat.
The present study has also shown that Ajj suppresses 
basal renin release from nephroblastoma cells on a short­
term and long-term basis. Ajj had no effect on cell 
growth. Ajj levels were high in the medium to which no Ajj 
had been added and this could be blocked by Enalaprilat 
treatment which caused stimulation of active renin (but not 
prorenin) release. Enalaprilat had no effect on cell 
growth (c.f. Geary et al., 1990). It would be interesting 
to look at the effect of Ajj on renin gene expression in 
nephroblastoma cells.
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10.8. Nephroblastoma cells as an immortal line.
At this stage, it would be very useful to establish 
the nephroblastoma cells as a permanent cell line. This is 
because, at present, the cells can be maintained in culture 
for up to 3 months only. Thereafter they start to senesce 
and reach a crisis from which they do not recover. The 
cells therefore have a finite lifespan. Thus, it would be 
useful to 'immortalise' the nephroblastoma cells.
However, while this has been shown to be successful 
using tumoral JG cells (Pinet et al., 1985), there have
been few attempts to immortalise a Wilms' tumour line. 
Maitland et al. (1989) attempted SV40 transformation by 
transfection of SV40 tumour antigen genes into the cells 
soon after establishment (Southern and Berg, 1982). These 
workers have reported that despite an extended life span of 
up to 35-40 passages, the SV40-WT cell lines also 
eventually reached a crisis, from which most of them did 
not recover. This group has also carried out cell fusions 
between immortalised kidney cells of normal and tumour 
origin and an indicator cell line (HeLa). However, they 
did not carry out these fusions for the purpose of studying 
renin release and there have therefore been no reports on 
the suitability of the cells for such studies.
10.9. Conclus ions.
In conclusion, therefore, the present study has 
demonstrated that human cultured nephroblastoma cells are 
responsive to some of the agents known to regulate renin
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release in vivo. Also that the cells possess adenylate
cyclase which is probably the mediator of 0-stimulated cell 
growth. The cells also possess guanylate cyclase activity 
which is probably the mediator of ANP-inhibited basal renin 
release.
In addition, ANP-stimulated cGMP probably interacts 
with 0-stimulated cAMP and in so doing can alter renin 
release and cell growth. It should be noted, however, that 
these observations do not rule out a role for Ca2+.
Furthermore, the present study has reported 
differences in the mechanisms by which isoprenaline and 
forskolin cause a long-term increase in renin release.
In the present study, second-messenger responses to 
these agents were investigated and it was deduced that an 
increase in [cAMP]_£ (and possibly a decrease in [cGMP]e) is 
instrumental in stimulating cell growth in this system.
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